InnovationsKapital: Latest News

companyNews - 23 Januari, 2012 - Cellartis: CELLARTIS IS A PARTNER IN CARDIONET, AN EU-PROJECT WITH THE AIM TO DEVELOP NOVEL THERAPEUTIC TOOLS FOR IDENTIFICATION OF HEART DISEASE

2012-01-24 12:41:56

About Cellectis stem cells: Cellectis stem cells speeds up the development of stem cell technology in particular to find a robust and reproducible way of controlling stem cell production and differentiation. Through the sharing of knowledge and expertise developed by the two companies forming cellectis stem cells - Cellartis and Ectycell – cellectis stem cells becomes a major, long-term and stable industrial player in the global marketplace. Cellartis AB is a premier provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. For more information, visit www.cellectis.com Disclaimer This press release and the information contained herein do not constitute an offer to sell or subscribe, or a sollicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above. For further information, please contact : Cellectis stem cells Cellartis AB Johan Hyllner Chief Scientific Officer Tel : +46 (0) 31 758 09 02 Johan.hyllner@cellectis.com Cellectis Philippe Valachs Company Secretary Tel: +33 (0)1 81 69 16 00 media@cellectis.com Calyptus Alexis Breton / Cyril Combe +33 (0)1 53 65 68 68 cellectis@calyptus.net Cellartis AB, part of Cellectis stem cells

companyNews - 19 January, 2012 - Projectplace: Projectplace Launches Next Generation of Mobile Apps for Business Collaboration

2012-01-20 12:07:06

Projectplace Documents, available for iPhone, iPad and Android devices, is loaded with features that help project members to work with all important documents related to their projects while on the go. The new generation of mobile apps illustrates Projectplace’s new product strategy in which mobile platforms play an important role. The increased commitment to mobile platforms stems from the increased usage of smartphones (70 per cent) and other mobile devices such as the iPad (10 per cent) among Projectplace users. With the new app, Projectplace has made its mobile offering available to Android devices for the first time. “We have found that our customers want access to the most popular Projectplace features in our mobile apps,” said Per Wising, product owner at Projectplace. “Many companies put their focus on the development of their software or web-based tools and regard mobile apps as a bonus. At Projectplace we have decided on a unified strategy in which web and mobile app development go hand in hand.” Projectplace Documents marks the beginning of a new generation of mobile apps. It was designed with a strong focus on document management, which is one of the most popular features. The App enables users to: • Read and comment on documents in their projects • Discover what documents co-workers are interacting with • Save documents on mobile devices for offline reading • Easily find the documents they worked with recently “We are planning to add a wide range of additional features,” said Wising. “Moving forward, new Projectplace functions will be added simultaneously to the web tool as well as the mobile app.” Projectplace Documents is available for iPhone and iPad on Appstore as well as for Android devices on Android Market. International Media Contact: Anna Ålenius Mathson, International PR Manager Phone: +46708930246, Email:anna.alenius.mathson@projectplace.com Press room for media: http://www.mynewsdesk.com/uk/pressroom/projectplace_international

companyNews - 13 Januari, 2012 - Oxeon: High-performance Composites

2012-01-17 12:44:02

Startup general aviation manufacturer Shark Aero (Hlboké, Slovak Republic) designed its composite-airframed, single-seat prototype ultralight aircraft (ULA), the shark UL, with a view toward reducing weight. European ULA aircraft (also known in Europe as microlights )are limited by the Joint Aviation Authorities (JAR-1) to a maximum empty weight of only 300 kg/660 lb, but they are allowed a top speed of 300 kmh (186 mph). For comparison, single-seat ultralights in the U.S. are limited to a maximum of 101 kmh/63 mph (two-place trainers can go a bit faster, 138 kmh/86 mph). Therefore, a key design imperative was low airframe weight in exchange for greater air speed. The anticipated side benefits included more responsive flight controls, a higher payload-carrying capability, reduced takeoff and landing distances, a better climb rate and improved fuel efficiency. After a first prototype failed to hit the design weight goals, the company approached Oxeon AB (Borås, Sweden)in late 2008 to test trademarked TeXtreme Spread Tow woven carbon fabrics. The fabrics are made in a novel process in which carbon tows are spread to form thin, flat tapes. Then, the tapes are woven together to make very thin fabrics with virtually no fiber crimp (the weave is visible in the photo at right). The resulting reinforcement has mechanical properties similar to a traditional cross-ply unidirectional material, but achieves those properties with less weight. Shark Aero tested the mechanical properties of several TeXtreme variants and found that TeXtreme offers mechanical and process advantages when they are compared to conventional carbon fiber-based reinforcement materials. In particular, composite parts could be redesigned to reduce weight without sacrificing essential strength. Further, the surface smoothness afforded by TeXtreme tape eliminated the need for an outer protective layer of glass fabric, cutting a labor-intensive step in the manufacturing process. As a result, Shark replaced the plane’s 200-g/m2 and 90-g/ m2 baseline fabrics with 160-g/m2 and 80-g/m2 TeXtreme fabrics, respectively. “By switching to TeXtreme, we saved 50 kg [110 lb] in total on the aircraft,” reports Shark Aero CEO Vladimir Pekar. He also notes that “on average, the weight of smaller parts, such as the stabilizer, elevator, rudder, spinner and landing gear doors, have been reduced by 60 percent. Weight savings of this magnitude allow us to build a faster airplane.” The plane’s fuselage now weighs just 41 kg/90 lb, which is 25 kg/55 lb less than the prototype made using conventional carbon fiber fabrics. Thanks to the lighter spread-tow fabrics, the program has been a success. “By switching to TeXtreme and performing finite element modeling,” Pekar says, “the unexpected 25-kg weight savings allowed us to meet the maximum empty weight of 300 kg/661 lb for a single-seat ULA and at the same time improve many crucial flight features.” shark UL airplanes are presently competing for world speed records and are aiming to reach the ULA speed limit in the near future.

companyNews - 10 January, 2012 - Cellartis: Cellartis is a partner in InnovaLiv, a major multinational regenerative medicine project funded by the European Commission

2012-01-11 13:01:10

InnovaLiv aims to provide the EU healthcare system with a renewable and reliable source of functional clinical-grade hepatocytes generated from hESC lines. Rigorous standards to ensure the safety and quality of these cells will be developed. The GMP-compliant hepatocytes will be prepared as a prototype therapy aiming at treating one patient on the basis of a compassive use protocol. Commercialisation of the novel GMP-grade stem cell derived hepatocytes will be performed by Cellartis AB, Cellectis Stem Cells, that will assume a leading role in InnovaLiv. Transplantation of donor hepatocytes has become an alternative to liver transplantation for the treatment of liver diseases. However, in addition to the complication imposed by severe shortage of donor livers, adult hepatocytes cannot be expanded in vitro. Therefore, there is a critical need to explore the potential of human stem cells, such as hESC, to generate sufficient quantities of functional human hepatocytes. However, the production of safe and functional human hepatocytes from hESC under GMP conditions for clinical applications remains to be achieved. About Cellectis stem cells: Cellectis stem cells speeds up the development of stem cell technology in particular to find a robust and reproducible way of controlling stem cell production and differentiation. Through the sharing of knowledge and expertise developed by the the two companies forming Cellectis stem cells - Cellartis and Ectycell – Cellectis stem cells becomes a major, long-term and stable industrial player in the global marketplace. Cellartis AB is a premier provider of stem cell derived products and technologies which will drive unprecedented innovations in drug discovery and regenerative medicine today and in the future. For more information, visit www.cellartis.com About Cellectis: Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, biological research and agriculture. Cellectis is listed on the NYSE-Euronext Paris Alternext market (code: ALCLS). To find out more, visit www.cellectis.com Download press release (pdf)

companyNews - 4 January, 2012 - Oxeon: TeXtreme® in the Dakar Rally

2012-01-11 12:55:02

Pewano team raced a PEWANO XC60 RR car, which they have developed themselves. PEWANO XC60 RR is a tubeframe chassis built for the Cross Country Rallies and the Dakar. The car has a design based on Volvo XC60 with a carbon fiber body, the Rally Raid car is, however, 180 mm wider than the regular XC60. For the bodywork composite parts the natural choice was TeXtreme® carbon reinforcements due its unique weight saving and mechanical performance benefits. TeXtreme® Spread Tow Reinforcements use spread tows to produce optimized reinforcements for ultra light composites. Spreading tows into very thin tapes enables production of both unidirectional and woven reinforcements that present improved mechanical performance and weight savings that are unrivaled compared to conventional reinforcements. Pewano, however, did not get an opportunity to compete to their capacity. Halfway into the first special a fire forced driver Alfie Cox and co-driver Jürgen Schröder to abandon the car. Very positively both Cox and Schröder got out of the car unharmed. Hans Sönksen, Team Manager of Pewano, says: “It was during the first stage between Mar del Plata and Santa Rosa de la Pampa, after a couple hours of faultless driving, that something went wrong. With the car gutted by the flames, it’s not possible to determine what caused the fire, but we believe that a leak in either the powersteering pump or one of the hoses in the powersteering system was the cause”. Driver Alfie Cox comments: “It could have been much worse, we escaped and we are shocked, but otherwise fine. I feel truly sorry for the team; they worked really hard in preparing the car. Now we will re-group, and plan our way forward." Download pdf About Dakar Rally The 2012 Dakar Rally will be the 33rd running of the event, and will be taking place in Argentina, Chile and Peru (starting in Mar del Plata and ending in Lima) from January 1st to January 15th. Almost 5,000 kilometers separate Mar del Plata from Lima, but the Dakar will be staging an adventure of more than 9,000 kilometers in total. Unlike previous year’s loops, the route will transport the rally from the shores of the Atlantic Ocean to those of the Pacific. The scale of this challenge has also led to a change in the race’s format, which will include 14 days of racing in 2012. The Dakar is not only an event of extremes. It's the largest motorsport event in the world, the largest competition with spectators on the spot and also the world’s third largest sports event. About PEWANO Pewano is a Swedish Cross Country Rally team with the goal to build competitive Rally Raid cars based on the Volvo XC60 to the prestigious Dakar Rally. The high-tech PEWANO XC60 RR rally car has been developed in collaboration with world-class mechanics and engineers, together with Volvo as a technical partner. Pewano want to showcase engineering expertise and solutions from Sweden and Scandinavia, as well as competing with the top rally teams worldwide. Pewano’s ambition is to build a very successful team for the Dakar. About Oxeon Founded 2003 in Sweden, Oxeon has quickly established itself as the market leader in Spread Tow Reinforcements. Use of these spread tow carbon reinforcements increases the mechanical performance of composite material products and reduces the weight. Utilization of Oxeon’s TeXtreme® Spread Tow Fabrics and TeXtreme® Spread Tow Tapes by manufacturers of advanced aerospace, automotive, industrial and sports products in applications that have critical material performance requirements has affirmed the significance of Oxeon’s ultra light materials. For further information please visit www.oxeon.se

companyNews - 22 December, 2011 - Apptus: Kjell & Company uses Apptus eSales boost online e-Commerce

2012-01-11 12:49:12

Apptus eSales smart and self-learning technology is fundamental to Kjell & Companies relaunched e-commerce site. Allowing personalized search, navigation, recommendations and campaigns for every individual shopper, Apptus e Sales boosts sales and adds a unique competitive advantage to Kjell & Company. “With more than 7000 of our own products and 5000 external products we provide accessories for, it is extremely important that customers immediately find what they’re looking for,” says Ulrika Klinkert, Head of Marketing at Kjell & Company. “We chose Apptus eSales because it gives our customers fast, accurate responses: it shortens their search by suggesting relevant products based on what other consumers with similar interests have bought. Apptus eSales reinforces Kjell & Company as Sweden’s best site for home electronics accessories.” With Apptus eSales, Kjell & Company customers can find what they are looking for in the company’s comprehensive selection. Apptus eSales learns from each visitor’s searches, navigations, clicks, product inspections, shopping cart contents and completed purchases. The powerful logarithm driving Apptus eSales, tracks each visitor’s digital path and automatically generates relevant search results and recommendations. Not only is Apptus eSales self-learning, it also helps customers find the right products even if they are spelled incorrectly using functions such as autocomplete and Did-you-mean. “Kjell & Company’s brand is strongly associated with a wide variety of products and outstanding customer service,” says Michael Mokhberi, CEO of Apptus Technologies. “Apptus’ job is to enable Kjell & Company to offer a top line online shopping experience for every customer – just as it does in its physical retail stores. Our intelligent self-learning technology also means that the site constantly improves and gains experience through user interaction, just like the real salespeople in store.” For more information please visit www.apptus.com

innkapNews - 8 December, 2011 - Inmeta Crayon: Inmeta Crayon ASA : Recommended voluntary cash offer to acquire 100% of Inmeta Crayon ASA

2012-01-03 16:36:40

The Offeror and Inmeta Crayon have entered into a transaction agreement regarding an acquisition of Inmeta Crayon by the Offeror. Under the terms of the agreement, the Offeror will put forward a recommended voluntary cash offer (the "Offer") for all of the shares of Inmeta Crayon. The consideration offered will be NOK 6.00 in cash per Inmeta Crayon share. This represents a premium of approximately 46 % to the closing share price of Inmeta Crayon on 7 December 2011, the last trading day prior to the announcement of the Offer and a premium of approximately 50 % to the one month volume weighted average share price of Inmeta Crayon for the period ended on 7 December 2011. The Offer values the total share capital of Inmeta Crayon at approximately NOK 831 million. The Offeror is not obliged to launch the Offer if EUR has depreciated by more than 5% against NOK at any time before 12:00 CET on 12 December 2011 compared to the EUR/NOK exchange rate at 18:00 CET on 8 December 2011. The Offeror is a special purpose vehicle currently owned by Norvestor V, LP and Norvestor V SBS, LP, acting by their general partner Norvestor V General Partner LP, acting by its general partner Norvestor V (GP) Limited. Norvestor V L.P. is a private equity investment fund with a capital base of approximately EUR 236 million. The fund's objective is to invest in strong growth companies in the Norwegian and Nordic market. After having reviewed the terms and conditions of the Offer, the Board of Directors of Inmeta Crayon is of the view that an acceptance of the Offer is in the best interest of the Company's shareholders. The Board has received a fairness opinion dated 7 December 2011 from First Securities AS. First Securities AS' fairness opinion provides that, as of the date thereof and based upon the information available per 7 December and subject to the assumptions, considerations, qualifications, factors and limitations set forth therein, First Securities is of the opinion that the Offer Price is fair and on market terms. The Fairness Opinion is subject to change in case of new material information. Management and other employees of Inmeta Crayon holding shares in the Company (the "Management Investors") have entered into an investment agreement with the Offeror, whereby the Management Investors will, conditional upon completion of the Offer and otherwise subject to customary conditions, transfer Inmeta Crayon shares owned by them representing approximately 36 % of the total share capital of Inmeta Crayon to the Offeror. Other shareholders representing approximately 5 % of the total share capital of Inmeta Crayon have already given their pre-acceptances to the Offer, subject to customary conditions. The shares to be transferred by the Management Investors to the Offeror, conditional upon the completion of the Offer, and the shares subject to the irrevocable pre-acceptances represent in aggregate approximately 41 % of the total share capital of Inmeta Crayon. Jarl Øverby, CEO of Inmeta Crayon, said, "We believe Norvestor will be a good new owner for Inmeta Crayon in order to help us to strengthen our positions in existing markets and to accelerate our plans to enter new markets. We look forward to embarking on a new journey together with Norvestor." Henning Vold, Partner in Norvestor Equity AS, said, "We have followed both Inmeta and Crayon for many years and we are impressed by the results achieved by management. We are excited about the opportunity to assist the company in its future development." The Offer will not be subject to any financing or due diligence conditions. The complete details of the Offer, including all terms and conditions, will be contained in an Offer Document to be sent to Inmeta Crayon shareholders following review and approval by the Oslo Stock Exchange pursuant to Chapter 6 of the Norwegian Securities Trading Act. As will be further detailed and specified in the Offer Document, the completion of the Offer will be subject to the following conditions being satisfied or waived by Offeror: (i) the Offer shall have been accepted by shareholders of Inmeta Crayon representing (when taken together with any shares acquired or agreed to be acquired by the Offeror other than through the Offer) more than 90 % of the issued and outstanding share capital of Inmeta Crayon, (ii) all approvals required from regulatory authorities for completion of the Offer shall have been obtained, (iii) all required third party approvals have been obtained, (iv) there having occurred no material adverse change, as defined in the transaction agreement, with respect to the Company and its subsidiaries, taken as a whole, (v) the Board of Inmeta Crayon shall not have amended or withdrawn its recommendation of the Offer, (vi) no intervention shall have taken place by any court or other governmental or regulatory authority which restrains or prohibits the completion of the Offer, and (vii) there shall have been no breach by Inmeta Crayon of the transaction agreement which entitles Offeror to terminate the transaction agreement. The Offeror is in the process of preparing an Offer Document which has been filed with the Oslo Børs. The Offer Document will be sent to Inmeta Crayon's shareholders as soon as it has been approved by Oslo Børs. Such approval is expected on or before 16 December 2011. The acceptance period for the Offer will be two weeks from the date of the Offer Document being released, unless extended by the Offeror. The Offer will not be made in any jurisdiction in which the making of the Offer would not be in compliance with the laws of such jurisdiction. This notification does not in itself constitute an offer. The Offer will only be made on the basis of the Offer Document and can only be accepted pursuant to the terms of such document. SEB Enskilda is acting as financial adviser to the Offeror in connection with the Offer. ABG Sundal Collier is acting as financial adviser to Inmeta Crayon in connection with the Offer. For further information, please contact: Henning Vold (Chairman of the Board of Metallic Invest AS) +47 90 87 95 81 henning.vold@norvestor.com Paal S. Raaholt (Chairman of the Board of Directors of Inmeta Crayon) +47 92 62 73 00 psr@inmeta.com Jarl Øverby (CEO of Inmeta Crayon) +47 98 21 70 09 jarl.overby@inmeta.com About Offeror The Offeror is a special purpose vehicle currently owned by Norvestor V, LP and Norvestor V SBS, LP, acting by their general partner Norvestor V General Partner LP, acting by its general partner Norvestor V (GP) Limited. Norvestor V L.P. is a private equity investment fund established on Guernsey with a capital base of approximately EUR 236 million. The fund`s objective is to invest in strong growth companies in the Norwegian and Nordic market. About Inmeta Crayon Inmeta Crayon focuses on advising enterprises with complex IT needs. The business focus is on software licence advisory, courses and consulting services. Inmeta Crayon has about 470 employees, and is present in Norway, Sweden, Denmark, Finland and Germany. Licensing provides licence advice to optimise commercial and legal terms in standard software contracts which ensure control, flexibility and cost savings for enterprises. Consulting provides IT consulting services for major enterprises. Technological knowledge combined with wide experience of selected sectors, solutions and project execution mean the consultancy business is well positioned in a developing market. Inmeta Crayon's revenues amounted to approx. NOK 1.5 billion in 2010, with an EBITDA of NOK 70 million (pro forma). The company is listed on the Oslo Stock Exchange (ticker is INM). This information is subject to the disclosure requirements according to Section 5-12 of the Norwegian Securities Trading Act. The Offer and the distribution of this announcement and other information in connection with the Offer may be restricted by law in certain jurisdictions. Offeror assumes no responsibility in the event there is a violation by any person of such restrictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Inmeta Crayon ASA via Thomson Reuters ONE www.inmetacrayon.com

companyNews - 15 December, 2011 - BoneSupport: Fredrik Lindberg är årets Ideonstipendiat

2011-12-15 19:28:59

Ideon Science Park kan i dag meddela att årets Ideonstipendium tilldelas Fredrik Lindberg, vd och medgrundare av BoneSupport AB. BoneSupport arbetar med ett keramiskt och injicerbart bensubstitut för behandling av bland annat benskörhetsfrakturer. Grunden till bolaget hämtades ur forskningen vid Ortopediska kliniken på Lunds universitet under ledning av professor Lars Lidgren. I dag, tio år efter BoneSupports bildande på Ideons första företagsinkubator har bolaget dotterbolag i USA, Nederländerna och Tyskland fördelat på drygt 30 medarbetare. ”Att få ta emot Ideonstipendiet av en så illuster skara som Ideonsocietetens ledamöter är ett erkännande utöver det vanliga. Som entreprenör sätter man alltid sitt företag och sina anställda i främsta rummet, men någon enstaka gång kan det vara glädjande att uppmärksammas personligen. Jag är både glad och stolt och har nu fått ytterligare bränsle till passionen att driva BoneSupport till ett internationellt framgångsrikt företag”, säger Fredrik Lindberg. Motiveringen lyder enligt följande: ”Årets Ideonstipendiat har sedan drygt tio år startat och byggt ett mycket lovande företag som nu går in i en kommersiell fas och har stora möjligheter att lägga världen framför sina fötter. Stipendiaten har en synnerligen utvecklad förmåga att kombinera såväl ledarskap som försäljning och dessutom är han forskare i själ och hjärta. Företaget som han byggt från ett vitt papper har tagit fram produkter som redan har hjälpt och kommer att hjälpa många människor till ett väsentligt bättre liv.” Genom starka finansiärer har BoneSupport kunnat dra in betydande riskkapital på totalt 490 miljoner och bara i år investerade Industrifonden, HealphCap och Lundbeck Ventures 170 miljoner kronor i bolaget. Den potentiella marknaden för bensubstitut inom enbart Europa är cirka 3 miljarder kronor och för USA-marknaden mångdubbelt mer. OM IDEON SCIENCE PARK Ideon Science Park är den första och största av Sveriges cirka femtio forskningsbyar - eller science parks som vi numera väljer att kalla dem. Parken bildades 1983 för att ta tillvara på alla idéer och innovationer som skapas på Lunds universitet och sedan dess har flertalet tekniska landvinningar haft sin början här; till exempel GSM-telefoni, Bluetooth-kommunikation och Axis nätverkskameror. På Ideon Science Park verkar i dag drygt 260 företag. Ideon Science Park ägs av Wihlborgs Fastigheter AB och Ikano Fastighets AB. www.bonesupport.se

companyNews - 15 December, 2011 - Oxeon: Snowboards latest TeXtreme® application

2011-12-15 19:21:31

Both the Blade (Freeride) and Duoblade (Freestyle) boards have been tested by team riders for a year and both models enter the market this winter. Fanatic Snowboards has connections to Fanatic Windsurfing who have had successful premium windsurfing boards released. The experience and success of these windsurfing boards gave Fanatic Snowboards the incentive to test TeXtreme®. Jerry Niedermeier, Product Manager of Fanatic Snowboards, says: “Based on Fanatic's experience with TeXtreme® collected in the past, we were able to combine ultra light weight with dynamic properties, while displaying the material used in transparent areas. We are extremely happy with the performance and the success on the market to date.” TeXtreme® is an optimized premium carbon reinforcement used in applications and products where there are extreme needs for weight savings and performance. For Fanatic Snowboards the optimal TeXtreme® reinforcement proved to be an unbalanced Spread Tow Fabric. This enables them to achieve greater strength and stiffness in the desired directions, which ultimately gives the snowboards the right feel. About Oxeon Founded 2003 in Sweden, Oxeon has quickly established itself as the market leader in Spread Tow Reinforcements. Use of these spread tow carbon reinforcements increases the mechanical performance of composite material products and reduces the weight. Utilization of Oxeon’s TeXtreme® Spread Tow Fabrics and TeXtreme® Spread Tow Tapes by manufacturers of advanced aerospace, automotive, industrial and sports products in applications that have critical material performance requirements has affirmed the significance of Oxeon’s ultra light materials.

companyNews - 15 December, 2011 - BoneSupport: Lloyd Diamond new CEO of BONESUPPORT

2011-12-15 19:13:42

By the recruitment of Lloyd Diamond BONESUPPORT is taking the next step in accelerating the commercialization of its Cerament oesteoconductive bone substitute. There is strong support and a firm commitment from the owners to build a world class company within the segment for injectable orthobiologics. “Lloyd’s very strong international experience from the device industry, including spine and orthopedics, will help us accelerate our ambitions to grow the company. I am very pleased that we have attracted Lloyd to join us with his solid commercial and operational background”, says Oern Stuge, Chairman of BONESUPPORT. “I am very excited about joining BONESUPPORT – an innovative high-tech company which has developed top class products based on solid scientific evidence. In addition, the company has an exciting pipeline of future orthobiologic products ”, says Mr. Diamond. Mr.Diamond has held positions in the medical device industry with leading global companies such as Laserscope, Kyphon and Conmed Linvatec; formerly Zimmer when it was a subsidiary of Bristol-Myers Squibb. He most recently served as the President Lumenis EMEA. Previously Mr. Diamond served as Sr. VP and General Manager of Lumenis’ Surgical and Vision businesses. He holds a BS Degree in Biochemistry and Marketing, as well as a Masters in Business Administration from Thunderbird School of Global Management in Arizona. Mr. Diamond will commence his new position at BONESUPPORT on Jan 16, 2012. Fredrik Lindberg, co-founder and current CEO will remain in the company as Chief Scientific Officer being responsible for key customer relations, driving the clinical publication program as well as the product development pipeline for “the first of itskind” products for the treatment and prophylaxis of deep bone and orthopedic prosthesis infections. “As a co-founder I am very pleased to get the chance to work with Lloyd. With his background from commercial operations within the international medtech industry I am convinced BONESUPPORT will expand more rapidly in the international market”, says Fredrik Lindberg. For additional information, feel free to call: Oern Stuge, Chairman of BONESUPPORT, +41 796 58 51 20 Lloyd Diamond, +46 46 286 53 79 Fredrik Lindberg, CEO +46 708 86 53 70 Press photos are available at www.bonesupport.com BONESUPPORT BONESUPPORTAB is an innovative Swedish medical technology company that specializes in the development of high-tech solutions for the treatment of osteoporotic fractures and deep bone infections. Founded in 1999, the company is eadquartered at Ideon Science Park in Lund, Sweden. BONESUPPORT has ubsidiaries in the United States, etherlands and Germany. Its key trademark is CERAMENT™.

companyNews - 8 December, 2011 - Inmeta Crayon: Inmeta Crayon ASA : Recommended voluntary cash offer to acquire 100% of Inmeta Crayon ASA

2011-12-09 17:38:08

companyNews - 30 November, 2011 - Oxeon: Oxeon honored with another growth award

2011-12-09 17:23:43

Andreas Martsman, VP – Head of business development of Oxeon, and Henrik Blycker, CEO, received awards for “The best international growth” and “The male rising star”. The jury’s motivation was: "With study allowance as the first venture capital these people have founded a company with cutting-edge technology that has grown fantastically fast. Attributes that have characterized the company's path forward are innovation, adaptation to customer needs and stubbornness." Oxeon develops, produces and markets TeXtreme® Spread Tow Reinforcements to the advanced composites industry. In 2010 Oxeon was awarded “Supergasell” as the fastest growing company in Sweden, see press release. About the competition Ernst & Young Entrepreneur Of The Year is one of the world's top awards for entrepreneurs. It is the first international award for entrepreneurs that with a clear vision and strong leadership skills build successful companies. The competition takes place at regional, national and international level in more than 140 cities in over 50 countries. The entrepreneurs are assessed by an external jury after the criteria entrepreneurial spirit, economic development, strategic direction, impact on the world, innovation and personal integrity and influence. The competition started in the U.S. in 1986. www.oxeon.se

companyNews - 30 November, 2011 - Santaris: United States Patent and Trademark Office upholds key Santaris Pharma A/S LNA patents in two re-examination cases brought by Isis Pharmaceuticals

2011-12-09 17:21:02

Hoersholm, Denmark/San Diego, California, November 30, 2011 — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has won two significant patent re-examination cases brought by Isis Pharmaceuticals, Inc. (Nasdaq: ISIS). The positive rulings by the United States Patent and Trademark Office (USPTO) cover two key Santaris Pharma A/S “Imanishi” patents, U.S. Pat. No. 6,268,490 (the “‘490 patent”) and U.S. Pat. No. 6,770,748, (the “‘748 patent”), which claim rights to the Locked Nucleic Acid (LNA) or Bicyclic Nucleic Acid (BNA) chemical structure used for developing antisense molecules. The United States Patent and Trademark Office (USPTO) revoked the ex parte re-examination of the ‘490 patent and provided a Notice of Intent to Issue a Reexamination Certificate that confirms the patentability of all claims of the ’490 patent owned by Santaris Pharma A/S and is not subject to appeal. In addition, the USPTO issued an Action Closing Prosecution in the inter-partes re-examination of ‘748 patent, which is a continuation-in-part of the ‘490 patent, confirming all of the original claims. “As the leader in developing LNA-based drugs, Santaris Pharma A/S is very pleased that the USPTO has ruled in favor of Santaris Pharma A/S and upheld the company’s “Imanishi” patents,” said Søren Tulstrup, President and CEO of Santaris Pharma A/S. “The USPTO rulings affirm the strong intellectual property position of Santaris Pharma A/S as it continues to develop effective RNA-targeted therapies with high affinity, target specificity and remarkable potency for a range of diseases both internally and with its partners.” Santaris Pharma A/S LNA Drug Platform combines the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states including infectious and inflammatory diseases, cardiometabolic disorders, cancer, and rare genetic disorders. The unique combination of pharmaceutical properties, small size and very high affinity of LNA-based drugs allows this new class of antisense drugs to potently and specifically inhibit RNA-targets in many different tissues without the need for complex delivery vehicles. “The positive USPTO rulings are very important as the Imanishi patents are one of the cornerstones of Santaris Pharma A/S significant patent estate, which broadly covers the 2’-4’ bicyclic nucleotide universe,” said Henrik Ørum, PhD, Vice President and Chief Scientific Officer of Santaris Pharma A/S. “Santaris Pharma A/S has dedicated its scientific know-how and expertise to advance LNA-based chemistries into a versatile LNA Drug Platform for the development of new RNA-targeted drugs for human diseases.” Santaris Pharma A/S has substantial intellectual property rights that includes ownership of more than 60 patent families which cover the LNA chemistry, manufacturing, therapeutic uses in patients and animals and optimal drug designs and drug formats. About Locked Nucleic Acid (LNA) Drug Platform The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combines the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver LNA-based drug candidates against RNA targets, both mRNA and microRNA, for a range of diseases including infectious and inflammatory diseases, cardiometabolic disorders, cancer and rare genetic disorders. LNA-based drugs are a promising new class of therapeutics that are enabling scientists to develop drug candidates that target previously inaccessible clinical pathways. The LNA Drug Platform overcomes the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The unique combination of small size and very high affinity allows this new class of drug candidates to potently and specifically inhibit RNA targets in many different tissues without the need for complex delivery vehicles. The most important features of LNA-based drugs include excellent specificity providing optimal targeting; increased affinity to targets providing improved potency; and favorable pharmacokinetic and tissue-penetrating properties that allow systemic delivery of these drugs without complex and potentially troublesome delivery vehicles. About Santaris Pharma A/S Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. Please visit www.santaris.com for more information.

companyNews - 17 november, 2011 - Projectplace: Rapidly-growing Projectplace passes the 700,000 user mark; sets sights on 1 million in 2013

2011-12-07 16:04:54

Projectplace the European leader in online project collaboration, today announced that the company has passed the monumental mark of 700,000 registered users worldwide. This is yet another milestone in the history of Projectplace. Despite hearing the odd champagne cork popping through its Stockholm headquarters, the Projectplace team is not resting on its laurels and already setting its sight on the next goal: breaking the 1 million mark in 2013. Imminent recruitment, both in R&D and in sales, and a focus on making the service even more intuitive and user friendly, will help Projectplace move from strength to strength its market-leading position. “This is a significant achievement, made possible by the entire team that has been extremely committed to turning Projectplace into the European leader in online project collaboration” said Johan Zetterström, CEO at Projectplace. “This is just the beginning. Our plan is to supercharge and expand our leading position in the field of online collaboration through substantial increases our R&D and sales activity.” When Projectplace was a small startup in the late nineties, businesses were still struggling to use the web for business collaboration. The young team had a vision to move all work routines to an online environment for collaboration in which projects could thrive and was influential in encouraging a wide range of organisations to adopt cloud collaboration. “The market is now mature and cloud-based work solutions are becoming the norm. This is reflected by the speed in which our user base has grown recently,” explains Johan Zetterström. “Projectplace has been a pioneer in its space and has laid the groundwork for online collaboration. Now we have reached a phase in which the real work begins: fighting off established software giants who want to get in on defining the new way of working online.” International Media Contact: Anna Ålenius Mathson, International PR Manager Phone: +46708930246, Email: anna.alenius.mathson@projectplace.com Press room for media: http://www.mynewsdesk.com/uk/pressroom/projectplace_international

companyNews - 24 november, 2011 - Besedo: Cecilia basar för Besedo i Malaysia

2011-11-30 13:16:49

Cecilia Carlsson har jobbat på Besedo sedan 2009, först på företagets kontor på Malta, där hon började inom kundservice och sedan arbetade upp sig till att bli teamledare för ett team på runt 30 personer i både Malta och i Sverige. Det tog sedan inte lång tid förrän hon erbjuden jobbet som operativ chef för bolagets kontor i Malaysia, som bolagets brofäste till marknaden i Asien. Där har hon varit sedan augusti i år. Svenska Besedo är ett svenskt outsourcingföretag som grundades 2002 och har 250 anställda fördelade på 15 språk, och kontor i Sverige, Malta, Frankrike och Malaysia. Bolaget är även internationellt sett ett stor aktör när det gäller användargenererat innehåll, det vill säga information som finns på, till exempel, dejtingsajter, köp- och säljsajter och spelsajter. – Förutom att vi hjälper onlineföretag med innehåll på deras sajter, så jobbar vi även med kvalitetssäkring och granskning av allt innehåll innan det publiceras, säger Cecilia Carlsson. Som kontorsansvarig på Besedo i Malaysia är hon förstås budgetansvarig, och hon ska också se till att leverera i tid och få in nya kunder. – Utmaningen i det fallet är att Malaysia inte är billigare än andra länder i Asien, säger hon. Hon har tidigare erfarenheter av att bo i Asien: – För några år, när jag var 20 år, pluggade jag kinesiska (mandarin) i Kina och ända sedan dess har jag längtat tillbaka till den här delen av världen. En av de stora utmaningarna i jobbet är förstås kulturskillnaderna, säger Cecilia Carlsson. Som ensam europé bland flera olika nationaliteter och språk, så kan det ibland brista i kommunikationen. Med engelska som gemensamt företagsspråk är det lättare att förstå varandra och komma till tals, hävdar hon. – Det är ett tufft jobb med många beslut att ta, men jag tycker att det är kul och samtidigt en stor utmaning. Jag har fått en chefposition utan att egentligen ha någon egentlig utbildning. Företaget har hela tiden stöttat mig och lärt upp mig från grunden, säger hon.

companyNews - 3 oktober, 2011 - Santaris: Santaris Pharma A/S to report new clinical data from miravirsen Phase 2a study to treat Hepatitis C in late-breaking oral presentation at the AASLD 2011 annual meeting

2011-11-30 13:12:31

Data from the Phase 2a trial showed that miravirsen, the first microRNA-targeted drug to enter clinical trials, provided continuous and prolonged anti-viral activity well beyond the end of active therapy in patients and was well tolerated in patients infected with HCV. These data demonstrate that miravirsen has the potential to be a once-weekly treatment for chronic HCV infection. The abstract titled, “A Randomized, Double-blind, Placebo Controlled Safety and Anti-viral Proof of Concept Study of Miravirsen, an Oligonucleotide Targeting miR-122, In Treatment Naïve Patients with Genotype 1 Chronic HCV Infection” will be presented in a late-breaking oral presentation on November 7 at 4p.m., at The Liver Meeting® 2011, the 62nd annual meeting of the AASLD, taking place from November 4-8 in San Francisco, California. The abstract is published on thewww3.interscience.wiley.com/journal/106570044/home at aasld2011.abstractcentral.com/login The randomized, double-blind, placebo-controlled, ascending multiple-dose Phase 2a study assessed the safety and tolerability of miravirsen in treatment-naïve patients with chronic HCV genotype 1 infection. Patients with chronic HCV genotype 1 infection were enrolled sequentially to one of three cohorts (9 active: 3 placebo per cohort). Miravirsen was given as weekly subcutaneous injections, over 29 days. Key data that will be presented demonstrate that miravirsen was associated with dose-dependent, prolonged reductions in HCV RNA that continued to fall after the completion of miravirsen therapy (see table 1). In Cohort 2, the mean of the maximum change from baseline in HCV RNA (log10 IU/mL) over the first 10 weeks was -2.710 vs -0.152 (p =0.020) in the miravirsen and placebo groups, respectively. In Cohort 2, five subjects had a greater than or equal to a 2 log10 decrease from baseline to week 10 and one patient became HCV RNA undetectable 10 weeks after the last dose of miravirsen (week 14) without the addition of standard-of-care (SOC). Cohort 3 is ongoing. Developed using Santaris Pharma A/S proprietary Locked Nucleic Acid (LNA) Drug Platform, miravirsen is an inhibitor of miR-122, a liver specific microRNA that the Hepatitis C virus requires for replication. Miravirsen is designed to recognize and sequester miR-122, making it unavailable to the Hepatitis C virus. As a result, the replication of the virus is effectively inhibited and the level of Hepatitis C virus is profoundly reduced. About Hepatitis C Hepatitis C is a viral disease caused by the Hepatitis C virus that leads to swelling (inflammation) of the liver. The World Health Organization estimates about 3% of the world’s population has been infected with HCV and that some 170 million are chronic carriers at risk of developing liver cirrhosis and/or liver cancer[1]. Approximately 3-4 million Americans are chronically infected with an estimated 40,000 new infections per year[2]. In Europe, there are about 4 million carriers. Treatment with the current standard of care, pegylated interferon in combination with ribavirin, is effective in only about 50% of those treated. Patients that are not effectively treated have an increased risk for the progression of liver disease. By 2029, total annual medical costs in the United States for people with Hepatitis C are expected to more than double, from $30 billion in 2009 to approximately $85 billion[3]. About microRNAs MicroRNAs have emerged as an important class of small RNAs encoded in the genome. They act to control the expression of sets of genes and entire pathways and are thus thought of as master regulators of gene expression. Recent studies have demonstrated that microRNAs are associated with many disease processes. Because they are single molecular entities that dictate the expression of fundamental regulatory pathways, microRNAs represent potential drug targets for controlling many biologic and disease processes. About Locked Nucleic Acid (LNA) Drug Platform The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combines the Company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver LNA-based drug candidates against RNA targets, both mRNA and microRNA, for a range of diseases including cardiometabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders. LNA-based drugs are a promising new class of therapeutics that are enabling scientists to develop drug candidates to work through previously inaccessible clinical pathways. The LNA Drug Platform overcomes the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The unique combination of small size and very high affinity allows this new class of drugs candidates to potently and specifically inhibit RNA targets in many different tissues without the need for complex delivery vehicles. The most important features of LNA-based drugs include excellent specificity providing optimal targeting; increased affinity to targets providing improved potency; and favorable pharmacokinetic and tissue-penetrating properties that allow systemic delivery of these drugs without complex and potentially troublesome delivery vehicles. About Santaris Pharma A/S Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the Company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The Company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The Company has strategic partnerships with miRagen Therapeutics, Shire plc, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the Company holds exclusive worldwide rights to all therapeutic uses of LNA. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. Please visit www.santaris.com for more information. Media Contact: Navjot Rai Director, Global Communications Santaris Pharma A/S Office: + 1 858 764 7064 ext. 206 Cell: +1 619 723 5450 e-mail: navjot.rai@santaris.com

innkapNews - 2 november, 2011 - Cellectis: Cellectis shareholders approve the acquisition of Cellartis. Cellectis decides to raise €50 million from the FSI and Mr. Pierre Bastid, and to grant free share purchase warrants to all existing shareholders.

2011-11-24 12:46:45

More specifically, Cellectis’ shareholders approved the following resolutions: • Operational takeover of Cellartis by Cellectis. In return for selling 100% of Cellartis’ capital, Cellartis’ shareholders will receive 1,933,333 Cellectis shares1 and €16.4 million in cash, subject to final completion of the €50 million financing round, • Appointment of Mr. Laurent Arthaud as a director, representing the FSI, replacing Mr. Richard Mulligan, following the latter’s resignation, and two new independent directors, Mrs. Annick Schwebig and Mr. Pierre Bastid, subject to final completion of the €50 million financing round. In addition, at the Board meeting held today following the shareholders’ meeting, the directors decided, upon delegation of the shareholders’ meeting, to: • Issue 6,250,000 convertible bonds at a price of €82 to be subscribed evenly by the FSI and Mr. Pierre Bastid (i.e. €25 million each), and • Grant share purchase equity warrants to Cellectis’ existing shareholders (not including the FSI, Mr. Pierre Bastid and Cellartis’ shareholders) on the basis of one share purchase warrant for each currently held share, with five share purchase warrants entitling their holder to subscribe for one new share at a price of €93, in order to enable them to participate in the Company’s development and limit the impact of the dilution relating to the acquisition of Cellartis and the new financing round. The free share purchase warrants will be granted on November 1st, 2011 to all of the Company’s shareholders based on the Euroclear France positions at October 31st, 2011. Subject to final completion of the acquisition of Cellartis and the new financing round, both to be carried out by November 4th, 2011, the share purchase warrants will be registered for trading on the Alternext market of NYSE Euronext Paris on November 7th, 2011 and could be exercised from the same day until October 28th, 2014. Not for release, publication or distribution, directly or indirectly, in Australia, Canada, Japan or the United States PAI-658667v6 A press release announcing the final completion of the acquisition of Cellartis and the new financing round4 will be published by the Company on November 4th, 2011. On October 28th, 2011, the French financial market authority (Autorité des marchés financiers, the “AMF”) granted visa number 11–488 to the prospectus relating to the allocation of the free share purchase warrants, comprising the reference document registered by the AMF on October 24th, 2011 under number R. 11-059 and a note d’opération (including the prospectus summary). The prospectus is available free of charge from Cellectis, 8, rue de la Croix Jarry, Paris 75013, France, and from Bryan, Garnier & Co., 26, avenue des Champs Elysées, 75008 Paris, France. It may also be downloaded from the Cellectis (www.cellectis.com) and AMF (www.amf-france.org) web sites. Cellectis would like to draw the public’s attention to the sections relating to the risk factors set forth in the prospectus approved by the AMF. If all or part of such risks were to occur, this might have a material adverse effect on the Company’s business, earnings, financial situation and prospects. André Choulika, Chairman and CEO of Cellectis: "The acquisition of Cellartis is in line with Cellectis’ strategy to become the global market leader for stem cell-based in vitro models and related technologies. It will make it possible to considerably accelerate our development in this field, while enhancing our commercial offers which are revolutionizing research and development for new applications across all life science industries. This major strategic step forward will all the more strengthen Cellectis’ potential that it is supported by the arrival of two reference shareholders. The FSI and Pierre Bastid represent decisive assets in terms of our goal to become one of the European life sciences industry leaders within five years". * * * About Cellartis Formed as a spin-off from the University of Gothenburg, Cellartis is a Swedish company with 10 years’ active experience in the development, industrialization and marketing of stem cell-derived cardiomyocytes and hepatocytes. Currently, these differentiated cells are mainly used for research and pharmaceutical clinical trials, and they offer unrivalled performance in toxicity testing. Cellartis’ unique position is based on its ownership and exploitation of the largest stem cell bank in the world (30 proprietary lines) and on the expertise in differentiation technologies that the company has developed since it was set up. The industrial rollout of these technologies has led to the creation of two certified sites in Sweden and Scotland. Alongside leading partners, Cellartis is involved in regenerative medicine programs which use the immense potential of stem cells for the restoration of damaged tissues and organs. Cellartis has 62 employees, all with a high level of scientific and industrial expertise. The company’s turnover in 2010 was €3 million. At June 30th, 2011, it had SEK 2.6 million in shareholders’ equity, SEK 7.5 million in net cash and zero financial debt (unaudited figures). For more information, please visit www.cellartis.com. About the FSI The FSI (Fonds Stratégique d’Investissement or Strategic Investment Fund) is a French limited company (société anonyme) owned by the Caisse des Dépôts (51%) and the French state (49%). It acts as an informed investor, taking minority stakes in promising French companies and industrial projects that create value and boost the competitiveness of the country’s economy. For more information, please visit www.fonds-fsi.fr. About Pierre Bastid Pierre Bastid is a French industrialist, and former Chairman of Converteam, the company he acquired from Alstom in 2005 with backing from investment funds and sold to General Electric in September 2011. Pierre Bastid will now be focusing on private investment, primarily targeting high-potential companies in emerging industries. About Cellectis Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, biological research and agriculture. Cellectis is listed on the NYSE-Euronext Paris Alternext market (code: ALCLS). For more information, please visit www.cellectis.com. Not for release, publication or distribution, directly or indirectly, in Australia, Canada, Japan or the United States PAI-658667v6 1 Representing a dilution of approximately 13.1% for existing shareholders on a fully diluted basis and before the conversion of the convertible bonds issued to the FSI and Pierre Bastid. 2 Representing a dilution of approximately 33% for existing shareholders, and an equity share of approximately 16.5% for each new investor, on a fully diluted basis after redemption of the convertible bonds, assuming that this redemption is based on a price of €8 per share (one share per convertible bond). The convertible bonds will include a coupon of 3.40% and will be redeemed early if Cellectis’ share price exceeds €8 for three consecutive trading days. Otherwise, their share redemption ratio, initially set at one share per convertible bond, could be adjusted upwards (maximum adjustment up to the reference share price retained for the issue) if the share price at maturity (three years) is below €8. 3 Representing 2,439,022 new shares if all the share purchase warrants are exercised, enabling the existing shareholders’ to increase their shareholding of up to approximately 10% on a fully diluted basis following the acquisition of Cellartis and the new financing round, assuming that the convertible bonds issued are subsequently converted into capital at a price of €8 per share. 4 Or, as the case may be, their postponement, as well as the postponement of the beginning of the exercise and trading periods of the share purchase warrants. Disclaimer This press release and the information contained herein do not constitute an offer to the public, an offer to subscribe, or the solicitation of the public in view of an offer of securities to the public. No offer of securities to the public will be made inside or outside France until a prospectus within the meaning of Directive 2003/71/EC is approved by the French Autorité des marchés financiers (AMF). The distribution of this press release in certain countries may be subject to specific regulations. This press release shall not be published, released or distributed, directly or indirectly, in Australia, Canada, Japan or the United States of America. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy securities of Cellectis in Australia, Canada, Japan, the United States or any other country. The shares, share purchase warrants, shares issuable upon exercise of the share purchase warrants, the convertible bonds and the shares issuable upon exercise of the convertible bonds of Cellectis (the “Securities”), if and when issued, may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933 as amended. The Securities have not been and will not be registered under the U.S. Securities Act and Cellectis does not intend to conduct a public offering of any of such Securities in the United States. This press release contains forward-looking statements, including statements about Cellectis’ business and prospects, its acquisition of Cellartis, and a potential offering of its Securities. Such forward-looking statements are based on data, assumptions and estimates that Cellectis considers to be reasonable. They are subject to numerous risks and uncertainties, including matters not yet known to Cellectis or not currently considered material by Cellectis, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in forward-looking statements include, among others, the development of economic conditions, financial markets and the markets in which Cellectis operates. For further information, please contact: Cellectis Philippe Valachs Company Secretary Tel: +33 (0)1 81 69 16 00 media@cellectis.com Marc Le Bozec Chief Financial Officer Tel: +33 (0)1 81 69 16 00 investor@cellectis.com Calyptus Alexis Breton / Cyril Combe Tel: +33 (0)1 53 65 68 68 cellectis@calyptus.net

companyNews - 2 november, 2011 - Cellectis: Cellectis shareholders approve the acquisition of Cellartis. Cellectis decides to raise €50 million from the FSI and Mr. Pierre Bastid, and to grant free share purchase warrants to all existing shareholders.

2011-11-02 17:51:25

companyNews - 27 oktober, 2011 - Oxeon: Composite hockey stick better than ever aided by TeXtreme®

2011-11-02 17:08:19

The BAUER Vapor APX is the premier stick in the BAUER Vapor stick line. Bauer Hockey has taken the foundation of the Vapor X:60 hockey stick and combined it with the exceptional puck feel of the TotalONE hockey stick; creating the company’s most technical advanced hockey stick to date. BAUER uses TeXtreme® Spread Tow Fabrics to reduce weight, improve the mechanical performance and for the superior surface smoothness that reduces the need for finishing drastically, compared to a conventional fabric. “By using TeXtreme®, BAUER has benefitted from the standard weight savings and mechanical improvements. At the same time, we have found the surface finish to be noticeably better with TeXtreme® than with conventional 3K weaves,” said Adam Gans, Director of Product Development for sticks at BAUER Hockey Inc. “In the APX stick TeXtreme® has contributed to the lighter blade and to the torsional stiffness that prevents blade deflection when shooting, which increases accuracy and improves balance”. Andreas Martsman, VP Business Development of Oxeon, says: “During the years of our cooperation with BAUER they have been gaining market share in the premium ice hockey sticks segment. We are happy for whatever contribution TeXtreme® has had on their success and this illuminates what we want for TeXtreme®, to be a strategic partner and to aid in giving our customers this kind of success on their respective markets”. The benefits from TeXtreme® come from the Spread Tow structure that makes it possible to achieve thinner laminates and that have straighter fibers with reduced crimp which optimize and strengthen the composite. The lesser crimp reduce amount of excess plastic and hence minimizing weight. The BAUER Vapor APX stick is currently available at retail locations throughout the world. For further information: www.oxeon.se

companyNews - 24 oktober, 2011 - MDS: First Aid for the CFO - MDS Lavastorm Analytics Checks Business Performance and Processes

2011-11-02 17:04:23

Chief financial officers who want to analyse their operations and identify processes that aren’t working well, can turn to software from MDS Lavastorm Analytics. Drew Rockwell, CEO at MDS Lavastorm Analytics, says one of the most common problems he sees in business operations is that companies are running their operations on Excel when they need more powerful, more comprehensive business software. Almost all companies use Excel somewhere in their financial close, but many run multiple Excel spreadsheets, often with the results from one cascading into the results of another. (See story on Imagine Software below) If a company has 20 spreadsheets feeding an SAP system, can it be sure that all the calculations in each are accurate? Read the full article at Forbes www.forbes.com

companyNews - 21 oktober, 2011 - Aepona: Aepona strengthens Leadership Team

2011-11-02 17:03:00

Firstly, Ingolf Ruh has been appointed Senior Vice President, Sales for EMEA and Asia. In this role, Ingolf is responsible for driving sales growth within our existing and prospective Network Operator customers across all markets outside the Americas. Ingolf joins us from Motive, an Alcatel-Lucent Company, where he built the EMEA and APAC Sales team and grew the business to a $80M operation. Prior to Motive and ALU, Ingolf worked for IBM and Tivoli Systems. Reporting to Ingolf will be all existing Network Operator sales staff in EMEA, as well as the EMEA/Asia Product Solutions Group (PSG). Secondly, Will Yapp has been appointed Senior Vice President, Global Cloud and OEM Sales. In this role, Will has dual responsibility for sales growth in the global Cloud Provider market, and the development of Aepona's indirect sales channels through relationships with Network Equipment Providers, Device Manufacturers and other potential OEM partners. Since joining Aepona in early 2010, Will has driven Aepona's early success in the Cloud Provider market, securing wins with Neustar and TNS. Prior to Aepona, Will was VP Worldwide Sales & BD at LiveWire Mobile, a leading provider of managed personalization services for mobile operators globally.

companyNews - 20 oktober, 2011 - Projectplace: Projectplace lanserar verktyg för resurshantering

2011-11-02 17:01:27

Projectplace lanserar idag ett samarbete med proventis GmbH. Med Blue Ant, proventis GmbH:s verktyg för resurshantering, erbjuds Projectplace användare möjlighet till förbättrad projektplanering, kontroll och utvärdering. Projectplace, europaledande inom projektsamarbete online, och proventis GmbH, utvecklare av Blue Ant, tillkännagav idag ett strategiskt samarbete som innebär att Projectplace kunder nu kan effektivisera sin projektorganisation genom Blue Ants resurshantering. Allt fler företag arbetar i projekt vilket resulterar i att resurshantering innebär en allt större utmaning. Organisationer behöver ständigt kunna se över resurstillgängligheten för pågående och framtida projekt. Detta är nödvändigt för att undvika flaskhalsar och förseningar som uppstår på grund av för få anställda och för lite resurser. – Vi är väldigt nöjda med att vi kan erbjuda våra kunder möjligheten till strategisk planering tillsammans med Blue Ant, säger Patrik Kjellin, Business Development Manager på Projectplace. Den process som krävs för att identifiera rätt resurser för kommande projekt kan vara tidsödande. Vi ser Blue Ant som den perfekta partnern eftersom de erbjuder ett okomplicerat verktyg som gör den här utmaningen mycket enklare. Andra viktiga kriterier för oss var att hitta en partner som ligger i linje med vårt Social Project Management-tänkande och som har öppna API-er. Den nya resurshanteringen innebär följande fördelar för Projectplace användare: Få en överblick över resurserna och deras kompetens för planerade och pågående projekt •Hitta befintliga resurser och använda dem på bästa sätt •Identifiera potentiella förseningar som orsakas av överbokade resurser innan de påverkar projektet negativt •Generera kostnads- och nyttjanderapporter för olika projektgrupper och avdelningar – Hos Projectplace har vi hittat en partner vars vision och mål kompletterar oss perfekt när det gäller projektsamarbeten, säger Norman Frischmuth, VD för proventis GmbH. Vi är otroligt glada över den enorma potential som användarna får tillgång till i sitt projektlednings- och resursplaneringsarbete när vi integrerar Blue Ant-modulen i Projectplace verktyg. Blue Ant har redan rönt stora framgångar inom olika branscher och bidragit med fördelar till sina användare, exempelvis Oberfinanzdirektion Niedersachsen, OFD: – Efter att vi införde resurshantering har vi fått en bra överblick över läget hos de regionala finanskontoren, säger Thomas Jahn, Resource Manager på OFD. Vi kan bland annat förse projektledare och projektmedlemmar med största möjliga kompetens i relation till olika färdigheter. Detta har ett strategiskt stort värde för vår personalutveckling. Verktyget Blue Ant är en tilläggsmodul till Projectplace. För mer information se, www.projectplace.se eller se en video med Patrik Kjellin här. Kontaktperson Projectplace för svenska medier: Emma Hansson, Country Marketing Manager Telefon: +46763633731, E-post: emma.hansson@projectplace.com proventis GmbH och Blue Ant proventis GmbH grundades 2001 som ett programvaru- och konsultföretag i Berlin. Företaget har för närvarande 30 anställda som arbetar med att utveckla enkla och effektiva lösningar för projektledning. Man erbjuder konsulttjänster och program från en enda källa och har utvecklat programvaran för multiprojektledning Blue Ant, ett helt webbaserat projektledningsprogram som hjälper användarna att planera, kontrollera och utvärdera sina projekt. Mer information finns på www.blueant.de Projectplace International har sedan 1998 utvecklat ett verktyg för projektsamarbete online. Verktyget stödjer " Social Project Management”” med fokus på samarbete och kommunikation i projekt. Projectplace är marknadsledande i Europa med sju språkversioner och över 690 000 registrerade användare. Företaget har 120 anställda med huvudkontor i Stockholm och lokala kontor i Frankfurt, Amsterdam, Oslo och Köpenhamn. Besök oss på www.projectplace.se

companyNews - 20 oktober, 2011 - MDS: Lavastorm Business Performance Analytics Suite and new corporate identity launched

2011-11-02 16:59:24

MDS Lavastorm Analytics specializes in Business Performance Analytics, enabling enterprises to analyze, optimize and control complex business processes to improve financial, operational and customer experience performance. Through software that enables discovery driven adaptive business analytics, reaching into operations, customer interaction and financial management, MDS Lavastorm Analytics already has a global customer base of 50 enterprises across 6 continents and is a market-leading solution provider in the communications industry. The Lavastorm Business Performance Analytics Suite is designed to revolutionize the business analytics industry. It enables enterprises to deliver business-centric and discovery-driven analytics across their business processes to drive faster and more transparent analytic results with greater levels of accuracy. It also enables business leaders to make better-informed decisions and control every stage of the analytic data process to back this up. The product suite provides software that both IT and business users can use to collaborate and improve business performance, as well as an adaptive framework that supports diverse and complex requirements. The Lavastorm Business Performance Analytics Suite includes: Lavastorm Analytic Platform (LAP). A platform which provides visual, discovery-driven capability across business processes to provide rapid value by identifying problems and resolutions faster and implementing effective business controls. Lavastorm Resolution Center. Provides control for analytic reporting, case management, and alarm management. Users can create audit and management controls easily, while case management capability provides advanced forensics and simplified routine operations to enhance business performance. Lavastorm Transaction Warehouse. An advanced system for Fraud and Usage based analytics, capable of managing billions of transaction records per day. Lavastorm Data Acquisition Module. A highly configurable module for multi-source and format data acquisition, overcoming technical and financial limitations for including complex data formats in the analytic process. Lavastorm BillAnalyzer. A converged multi-service e-billing and analytics software solution, that provides service providers with the ability to enable their business customers with easy to use self-care e-billing & analytics in a single view, to simplify the management of today’s enterprise communications estate. "Adding intelligence into process operations improves efficiency and effectiveness, and is a key part of a continuous improvement initiative," said Bill Gassman, Research Director, Business Intelligence of Gartner Research. "However, this is difficult to achieve. Challenges include being able to conduct analytics across complex business processes with multiple data sources, identifying where problems such as data or process execution inaccuracies are occurring and then how to implement persistent controls. As these enterprise issues continue to grow, it is key that discovery driven analytics with clear business context sits side by side with enterprise business processes to aid the analysis, optimization and control of business performance." Drew Rockwell, CEO of MDS Lavastorm Analytics, commented "As the volume of enterprise data increases, so has the need for greater ease of use, accuracy and speed of results in the business analytics market. We are developing our company and our solutions to support the continued growth in the market, and to provide innovative solutions to our ever-expanding customer base. Our Lavastorm Analytic Platform (LAP) is revolutionizing the way in which IT and business users alike can drive faster and more transparent value with analytics across enterprise business processes, across any industry." As well as the additions to its product portfolio, MDS Lavastorm Analytics also announces today a new corporate identity, as it builds on its success in the market place. Currently over 50 enterprises in 6 continents use its analytic software and services to drive greater levels of business performance across their enterprise operations. In addition, Christopher Grahn has joined the MDS Lavastorm Analytics executive team as Managing Director for Asia Pacific, to build on the current customer base and success in the region to drive and support the next level of expansion and growth. Mr. Grahn joins from Digital Route AB, where he was Managing Director for APAC and MEA. www.martindawessystems.com

companyNews - 18 oktober, 2011 - Paxport: Paxport and Sunway Holidays sign ancillary revenue agreement

2011-11-02 16:56:07

On selected Sunway Holiday charter flights, Customers will be able to preselect specific seats via an aircraft seat map which will also allow the selection of extra leg room seats and front row seats. These seats can be selected online or via a dedicated call centre. Passengers can book via the Paxport website extras.paxport.net/?language=en, or via the dedicated call centre number 0766060761. Drew Duggan, COO Sunway Holidays commented, "It is our aim to give our Customers the highest service and choice and we are exciting to be co-operating with Paxport and pleased to be offering the ability for our Customers to pre-select seats and extra leg room seats on selected charter flights, initially for the remainder of this Summer season". Carl Denton, Sales Manager, UK & Ireland commented "Paxport is very happy to be launching the Paxport Extras product in Ireland with Sunway Holidays and we look forward to developing both the product offering and the range of available flights in the future to ensure we can help enhance the Customer experience for Sunway Customers". The Sunway Travel Group is the largest and only Irish owned operator to offer a full selection of holiday options including: Summer and Winter Sun, Worldwide, USA & Canada Cruise, River Cruise and Sunsail, Club Med, Escorted Tours, Weddings & Honeymoons and Lapland. Paxport is Europe's leading ancillary revenue supplier for the charter airline industry and offers its airline and tour operator customers the means to generate additional revenues by giving passengers the opportunity to buy choice of seating, extra baggage, meals and other products before the flight and a solution for collecting security APIS data - all services have the added feature of giving airlines and tour operators a new touch point to offer sales of products and services to the passenger.

companyNews - 18 oktober, 2011 - Santaris: Servier and Miragen Sign $352 Million Partnership Agreement for the Research, Development and Commercialization of MicroRNA-targeting Drugs for Cardiovascular Disease

2011-11-02 16:44:55

SURESNES, France, and BOULDER, Colo., October 18, 2011 – Les Laboratoires Servier, a leading European pharmaceutical company with expertise in innovative treatments for cardiovascular diseases, and Miragen Therapeutics, Inc., a preclinical-stage biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today an agreement for advancing the research, development and commercialization of three drug candidates, including two of miRagen’s lead programs (miR-208 and miR-15/195) and one additional target yet to be identified, for cardiovascular disease. This partnership provides worldwide rights, excluding the U.S. and Japan, to Servier. Under the terms of the agreement, Miragen will receive up to $45 million in total upfront, research support and near-term milestone payments over the next three years, as well as royalties on sales, based on the successful outcome of the collaboration. Additional clinical and commercial milestones, as well as clinical development support for the successful development of the three compounds, would value the deal at approximately $1 billion. Miragen and Servier will collaborate on the research and development effort, while Servier alone will be responsible for all costs associated with the global development, regulatory approval and commercialization of the three product candidates worldwide, excluding the U.S. and Japanese markets. Miragen retains all rights in the U.S. and Japan, and the option to co-sponsor any Phase III programs in the event that Miragen, alone or together with a partner, should seek marketing approvals for any of the targets in the U.S. and Japan. “We are very pleased with this new partnership, which demonstrates once again our ability to explore truly innovative treatments for patients suffering from cardiovascular diseases. Indeed, these diseases still represent the number one cause of mortality in most of the world,” said Emmanuel Canet, M.D., Ph.D., Head of Servier R&D. “More and more evidence is gathering to show that some microRNAs are not only cardiovascular biomarkers, but they also play a significant role in the pathogenesis of various diseases from heart failure to coronary disease,” added Dr. Jean-Paul Vilaine, Head of Servier’s Cardiovascular Unit. “Our agreement with Servier not only provides validation of our lead programs in cardiac disease, but further underscores the potential of our innovative technology platform to deliver compelling drug candidates,” said William S. Marshall, Ph.D., President and Chief Executive Officer of Miragen Therapeutics, Inc. “We are delighted to partner with Servier, whose demonstrated leadership and expertise in the development of cardiovascular drugs are truly impressive. By combining our strengths, we hope to translate the potential of microRNA targeting into life-changing medicines for patients in need.” Miragen’s lead programs utilize Santaris Pharma A/S’ Locked Nucleic Acid (LNA) Drug Platform. In June 2010, Miragen licensed the rights to utilize Santaris Pharma A/S proprietary LNA Drug Platform to identify and select drug candidates against Miragen’s proprietary microRNA targets for the treatment of cardiovascular disease. This agreement has now been expanded to allow Miragen to develop additional targets and provide Servier access to Santaris Pharma’s LNA technology. “We are pleased to expand our alliance with Miragen to include additional cardiovascular targets and provide access to Santaris Pharma’s LNA technology in order to help Servier and Miragen to develop LNA-based microRNA-targeted drugs for the treatment of cardiovascular disease,” said Søren Tulstrup, President and CEO of Santaris Pharma A/S. “This agreement further validates that Santaris Pharma’s LNA Drug Platform is the technology-of-choice for developing RNA-targeted medicines.” The agreement includes two of Miragen’s lead programs: miR-208, which plays an important role in the pathogenesis and progression of heart failure, and miR-15/195, which plays a role in the survival and proliferative capacity of cardiomyocytes. The agreement also includes one additional cardiovascular microRNA modulator yet to be identified. miR-208: Miragen’s research has demonstrated that therapeutic inhibition of miR-208 may improve cardiac function and survival rates during heart failure. In addition, chemically-synthesized inhibitors of miR-208 have been shown to suppress pathological cardiac remodeling in a model of heart failure induced by chronic high blood pressure, while enhancing cardiac function and survival. miR-15/195: Research has shown that the inhibition of miR-15 may stimulate cardiomyogenesis, the process whereby new heart muscle cells are formed, and that inhibition of miR-15 can spare cardiomyocytes from death during myocardial infarction (MI), resulting in less heart tissue death and an improvement in cardiac function after a heart attack. About Servier: Servier is the leading independent pharmaceutical company in France with sales worldwide reaching EUR3.7 billion in 2010. Servier is established in 140 countries with its main therapeutic products treating cardiovascular diseases, diabetes, CNS disorders, oncology and rheumatological diseases. More than 25 percent of Servier’s turnover is invested in research and development. Servier has more than 20,000 employees worldwide, including nearly 3,000 in R&D. For more information, please visit www.servier.com. About Miragen Therapeutics: Miragen Therapeutics, Inc., was founded in 2007 to develop innovative microRNA-based therapeutics for cardiovascular and muscle disease. Only recently discovered, microRNAs are short, single-stranded RNA molecules encoded in the genome that regulate gene expression and play a vital role in influencing cardiovascular and muscle disease. Cardiovascular disease is the leading cause of death globally and represents an enormous burden on global healthcare systems. Principally funded through venture capital investments, miRagen combines world recognized leadership in cardiovascular medicine with unprecedented in-house expertise in microRNA biology and chemistry. For more information, please visit www.miragentherapeutics.com. About microRNAs: MicroRNAs have emerged as an important class of small RNAs encoded in the genome. They act to control the expression of sets of genes and entire pathways and are thus thought of as master regulators of gene expression. Recent studies have demonstrated that microRNAs are associated with many disease processes. Because they are single molecular entities that dictate the expression of fundamental regulatory pathways, microRNAs represent potential drug targets for controlling many biologic and disease processes. About Santaris Pharma A/S’ Locked Nucleic Acid (LNA) Drug Platform: The LNA Drug Platform developed by Santaris Pharma A/S leverages the Company’s proprietary LNA chemistry to rapidly deliver LNA-based drug candidates against RNA targets, both mRNA and microRNA, for a range of diseases. LNA-based drugs are a promising new class of therapeutics that are enabling scientists to develop drug candidates to work through previously inaccessible clinical pathways. The unique combination of small size and very high affinity allows this new class of drugs candidates to potently and specifically inhibit RNA targets in many different tissues without the need for complex delivery vehicles.

companyNews - 13 oktober, 2011 - Xtract: Xtract and Nokia Siemens Networks collaborate to help mobile operators enhance customer experience

2011-11-02 16:42:32

With advanced capabilities for analysing and segmenting customers, the solution helps operators reduce churn and target their marketing campaigns more effectively. When integrated with other capabilities in the Nokia Siemens Networks’ offering for Customer Experience Management, such as campaign management, the Social Analytics solution strengthens the insight generated for the departments across the operator organisation. “Nokia Siemens Networks offering provides a superior platform for our advanced predictive analytics solutions to deliver industry’s best prediction accuracy, below-the-line take-up rates, and profiling for automated customer experience management,” says Mika Lindholm, CEO of Xtract. “Operators around the world will be able to unleash the power of subscriber data, including insight from social networks. For their customers, the benefits are proactive and relevant response to their needs, personalisation of marketing campaigns, and more effective customer care.” “Social Analytics is a powerful tool to enhance the customer experience, which is a top priority for many operators. It provides valuable insight for automated action, such as targeted promotions, to reduce churn and increase subscriber ARPU. In one of our recent projects for an operator in the Middle East and Africa we demonstrated improved results of the monthly promotion campaigns by more than 100%,” says Matthew Dove, Head of Solutions and Portfolio Management in Consulting and System Integration, Nokia Siemens Networks. The Xtract solution will be offered to the market as part of the overall Nokia Siemens Networks Business Solutions portfolio and as a stand-alone product. www.xtract.com

companyNews - 13 oktober, 2011 - Santaris: Santaris Pharma A/S obtains favorable ruling in arbitration proceedings against Exiqon A/S

2011-11-02 16:39:09

Hoersholm, Denmark/San Diego, California, October 13, 2011 — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today provided clarification on the arbitration court's ruling as a consequence of imprecise market information regarding the outcome of the arbitration proceedings initiated by Exiqon A/S in 2010 against Santaris Pharma A/S. On Friday, October 7, 2011, all of the allegations initiated by Exiqon A/S against Santaris Pharma A/S were dismissed by the arbitration court. The ruling furthermore confirms that Santaris Pharma A/S holds exclusive worldwide rights to manufacture, have manufactured, and sell products that comprise LNA as active ingredient for studies performed with a purpose of developing LNA-based drugs for marketing approval. Exiqon does not have rights to manufacture or sell such products. “This is clearly a win for Santaris Pharma A/S and the company is pleased with the decision by the court as it did not find in favor of any of the claims initiated by Exiqon and further confirms important exclusive rights of Santaris Pharma A/S,” said Søren Tulstrup, President and CEO of Santaris Pharma A/S. “Due to imprecise market information regarding the arbitration court's ruling, it is important to reiterate that Santaris Pharma A/S holds exclusive worldwide rights to products that contain LNA as an active ingredient for studies performed with a purpose of developing LNA-based drugs for approval.” During the arbitration proceedings it was further acknowledged that Santaris has the exclusive right, including the right to sublicense, to perform research of pharmaceutical products that comprise LNA as part of the active ingredient. As part of the court’s ruling, Santaris Pharma A/S was awarded 2 million DKK in reimbursement of legal costs payable by Exiqon. Santaris Pharma A/S is committed to developing LNA-based medicines in the areas of infectious diseases and cardiometabolic disorders and collaborating with its partners in a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. About Locked Nucleic Acid (LNA) Drug Platform The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combines the Company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver LNA-based drug candidates against RNA targets, both mRNA and microRNA, for a range of diseases including cardiometabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders. LNA-based drugs are a promising new class of therapeutics that are enabling scientists to develop drug candidates to work through previously inaccessible clinical pathways. The LNA Drug Platform overcomes the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The unique combination of small size and very high affinity allows this new class of drugs candidates to potently and specifically inhibit RNA targets in many different tissues without the need for complex delivery vehicles. The most important features of LNA-based drugs include excellent specificity providing optimal targeting; increased affinity to targets providing improved potency; and favorable pharmacokinetic and tissue-penetrating properties that allow systemic delivery of these drugs without complex and potentially troublesome delivery vehicles. About Santaris Pharma A/S Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the Company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The Company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The Company has strategic partnerships with miRagen Therapeutics, Shire plc, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the Company holds exclusive worldwide rights to manufacture, have manufactured and sell products that comprise LNA as active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. Please visit www.santaris.com for more information. Media Contact: Navjot Rai Director, Global Communications Santaris Pharma A/S Office: + 1 858 764 7064 ext. 206 Cell: +1 619 723 5450 e-mail: navjot.rai@santaris.com

innkapNews - 15 September, 2011 - Cellartis: SWEDISH STEM CELL COMPANY CELLARTIS TO BE ACQUIRED BY FRENCH BIOTECH COMPANY CELLECTIS

2011-10-05 11:46:13

“We are extremely delighted to take the next transformative steps and continue to build on our stem cell platform together with Cellectis" said Johan Hyllner, CEO of Cellartis. “In my opinion, the deal represents a giant leap forward in creating a strong industrial corporation, encompassing many new innovations and entering the stem cell and regenerative medicine arena.” “We are enthusiastic to have the opportunity to combine Cellartis’ world-renowned expertise in pluripotent stem cells-based industrial applications with Cellectis’ highend genetic engineering platform. Together, we will be in a position to accelerate the development of stem cell based solutions including therapies targeting diseases reputed as incurable thanks to regenerative medicine”, underlines Gunnar Fernström, Chairman of Cellartis, adding he is “convinced that the industrial platform and the stem cell- based products developed by Cellartis during the last decade are very valuable assets which will significantly contribute to the creation of a world leader in stem cells”. “The acquisition of Cellartis demonstrates our will to accelerate our development via targeted, relevant external growth operations” declares André Choulika, co Founder, Chairman and CEO of Cellectis. “At Cellectis, we are very pleased to continue to build on Cellartis’ unique stem cell platform in synergy with our genome editing technology.“ In return for the full divestment of their stake, Cellartis shareholders will receive 16.4 million euro in cash and 1.93 million Cellectis shares. Danske Bank Corporate Finance and Advokatfirman Vinge are acting as advisors to Cellartis and its owners on this transaction. Cellartis Enquiries: Dr. Johan Hyllner Chief Executive Officer (+46) 317580902 johan.hyllner@cellartis.com Gunnar Fernström Chairman of the Board (+46) 31609192 gunnar.fernstrom@innkap.se About Cellartis: Cellartis AB is a premier provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the world's largest single commercial source of ethically derived hES cell lines and has developed more than 30 cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001, has over 60 employees and is located in Gothenburg, Sweden and Dundee, Scotland, UK. For more information, please visit www.cellartis.com About Cellectis: Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris. For further information about Cellectis, please visit: www.cellectis.com Follow Cellectis on twitter: twitter.com/cellectis

innkapNews - 31 May, 2011 - Ignis: InnKap 3 Partners have sold the shareholding in Ignis ASA

2011-06-01 16:57:50
Finisar Corporation has now successfully completed its voluntary public cash offer to acquire the outstanding shares of Ignis ASA, a Norwegian company whose shares are listed on the Oslo Stock Exchange (OSE: IGNIS), at a cash price of NOK 8 per share. Since April 2009, InnKap 3 Partners have been a shareholder in Ignis ASA. InnKap 3 Partners became a shareholder in Ignis through the sale of Syntune AB to Ignis. Ignis ASA is an innovative provider of optical components and network solutions for fiber optic communication. Stockholm May, 2011 For more information, please contact: Peder Holm, Investment Director, InnovationsKapital, +46 8 54 50 14 93, +46 703 46 57 70, peder.holm@innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 70 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, Nor dNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 13 May, 2011 - InnovationsKapital: InnKap 4 Partners L.P. acquires stake in Paxport

2011-05-13 13:57:47
Paxport enables the charter airline business to move as the banking industry has done, allowing the passenger to do more themselves while adding value to the booking process. This reduces cost and enables higher levels of utilisation & efficiency in the industry. Paxport’s product and service platform is proprietary and developed in house. The business model is based on an outsourcing or software as a service concept where Paxport becomes a strategic partner on a revenue share model. The risk to the customer, set up and fixed costs are minimal and their operational needs are managed by Paxport. Paxport also turns certain regulations into sales opportunities such as check-in and security requirements. “We are very pleased to have InnKap 4 Partners as a new shareholder. We see no changes in our current strategy, but InnKap will add momentum and help us speed up the development to satisfy our customers’ needs”, says Patrick Lindblom, CEO at Paxport. InnovationsKapital invests in Nordic technology companies with strong growth. “For InnKap 4 Partners, Paxport offers the opportunity to become an owner in a well managed growth company that is pioneering the market with its ancillary revenue platform for the leisure travel industry in Europe”, says Peder Holm, responsible for InnovationsKapital’s investment in Paxport. For more information, please contact: Patrick Lindblom, CEO, Paxport +46 70 322 55 85 patrick.lindblom@paxport.se Peder Holm, Investment Director, InnovationsKapital +46 8 54 50 14 93 +46 703 46 57 70 peder.holm@innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 70 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 25 February, 2011 - InnovationsKapital: InnovationsKapital’s fund, InnKap 3 Partners, and other owners of Jolife AB have signed an agreement to sell their shareholding in Jolife to Medtronic, one of the world’s leading medical technology companies.

2011-02-25 16:27:36
Founded in 2000, Jolife AB develops and manufactures the LUCAS Chest Compression System, a medical device for heart-lung-resuscitation. Jolife’s vision is to save more lives and to increase the quality of life of sudden cardiac arrest victims. InnovationsKapital made its initial investment in Jolife, together with CapMan-managed fund Swedestart Life Science, in 2003. Jolife is located in Lund in Southern Sweden and employs 21 people. “We are pleased that Medtronic, a clear leader in the resuscitation space, has recognized the potential of Lucas® and Jolife. This is a proof that Swedish medical technical research is world leading and through this transaction Swedish innovation gets a global distribution. Jolife’s management and personnel have done an excellent job to reach the position of today. ”, says Ulf Tossman at InnovationsKapital. Prior to the transaction InnKap 3 Partners owned 20 % of the shares in Jolife AB.

innkapNews - 9 February, 2011 - InnovationsKapital: Emric acquires Financial Systems - is now the biggest IT supplier in the Nordic region within credit financing

2011-02-14 12:17:47
During 2010 Emric achieved sales of SEK 92 million, while Financial Systems reached SEK 55 million (preliminary figures). The acquisition means that the company now has customers in more than 20 countries.
“The acquisition provides us with much greater expertise within e.g. leasing, and it accelerates our international expansion, even though the Nordic region will continue to be our primary market,” comments Joakim Dahlgren, Emric’s CEO.
The newest – and largest – owner in the new company is InnovationsKapital, with a shareholding of 26%.
“Emric enjoys an extremely strong position in its market, and we are optimistic about the company’s opportunities for continued growth not only in the Nordic region, but also internationally,” adds Peder Holm, Investment Director at InnovationsKapital.
Emric plans to recruit 10 or more additional employees during 2011. Among its customers are many banks and credit institutions in the Nordic market such as Danske Bank, Länsförsäkringar bank, Handelsbanken, ICA Banken, Nordea, SBAB, SEB, Swedbank and Xerox.
“Our roots are in software development but we are becoming more and more of a total partner for our customers in everything that concerns their credit processes. The credit process takes far too much time at many credit institutions and this costs customers a lot of money. By using smarter processes and more efficient systems we can achieve great savings, as can our customers,” states Joakim Dahlgren.
For further information, please contact: Joakim Dahlgren, Group CEO and CEO at Emric Tel: +46 8 400 28 400, Mob: +46 70 979 0305 joakim.dahlgren@emric.com About Emric Emric offers banks and credit institutions business expertise, outsourcing and systems support for the various stages of the credit process. The company’s history stretches back to Öhman’s investment bank founder Emric Öhman. Öhman Financial Systems became Emric in 2001 and since then annual sales have increased from SEK 24 million to SEK 92 million today (2010). www.emric.se For further information, please contact: Peder Holm, Investment Director, InnovationsKapital, +46 31 60 91 90 peder.holm@innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 65 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 9 Januari, 2011: InnovationsKapital: Emric förvärvar Financial Systems AB -blir största IT-leverantören i Norden inom kreditgivning

2011-02-11 11:29:44
Under 2010 omsätter Emric 92 miljoner kronor och FSAB omsätter 55 miljoner kronor (preliminära siffror) Efter förvärvet har företaget kunder i över 20 länder.

Förvärvet ger oss mycket djupare expertis inom bland annat leasing och det påskyndar vår internationella expansion, även om Norden fortsätter att vara vår primärmarknad, kommenterar Joakim Dahlgren, VD på Emric.
Ny och tillika största ägare i det nya bolaget är InnovationsKapital som äger 26%.
Emric har en mycket stark position på sin marknad och vi är optimistiska kring bolagets möjligheter att fortsätta växa i såväl Norden som internationellt, kommenterar Peder Holm, Investment Director, InnovationsKapital.
Emric planerar att rekrytera ytterligare ett tiotal nya medarbetare under 2011. Bland kunderna märks flertalet banker och kreditinstitut på den Nordiska marknaden såsom Danske Bank, Länsförsäkringar bank, Handelsbanken, ICA Banken, Nordea, SBAB, SEB, Swedbank och Xerox.
Vi har vårt ursprung i mjukvaruutvecklingen men vi blir allt mer av en helhetspartner till våra kunder i allt som rör deras kreditprocesser. Hos många utlåningsföretag tar kreditprocessen alldeles för lång tid och det kostar dem mycket pengar. Genom smartare processer och effektivare system kan vi uppnå stora besparingar tillsammans med våra kunder, menar Joakim Dahlgren.
För mer information vänligen kontakta: Joakim Dahlgren, Koncernchef och VD på Emric +46 8 400 28 400 joakim.dahlgren@emric.com Om Emric Emric erbjuder banker och kreditgivare verksamhetskompetens, outsourcing och systemstöd för de olika stegen i kreditprocessen. Företagets historia går tillbaka till investmentbanken Öhmans grundare, Emric Öhman. Öhman Financial Systems blev Emric 2001 och sedan dess har omsättningen ökat från 24 miljoner kronor till 92 miljoner kronor (2010). www.emric.se För mer information vänligen kontakta: Peder Holm, Investment Director, InnovationsKapital, +46 31 60 91 90 peder.holm@innkap.se InnovationsKapital InnovationsKapital, som grundades 1994, är ett ledande venture capital bolag som investerar i unga, innovativa tillväxtföretag i Norden. Verksamheten bedrivs via kontor i Göteborg och Stockholm och fokuserar på Nordiska investeringar i ICT och Healthcare & Life Scieneces – dynamiska sektorer som är starkt växande och där nordisk forskning och utveckling har en framträdande plats. InnovationsKapital är rådgivare till fyra fonder som sammanlagt har 323 MEUR i förvaltat kapital från både svenska och internationella investerare. Ytterligare information finns på www.innkap.se

innkapNews - 18 October, 2010 - InnovationsKapital: InnKap 4 Partners L.P. acquires stake in Oxeon AB

2010-10-18 14:56:33
Founded in 2003, Oxeon has quickly established itself as the market leader in Spread Tow reinforcements. Use of these Spread Tow carbon reinforcements increases the mechanical performance of composite material products and reduces the weight. Utilization of Oxeon’s TeXtreme® Spread Tow Fabrics and TeXero® Spread Tow Tapes by manufacturers of advanced aerospace, automotive, racing, industrial and sports products in applications that have critical material performance requirements has affirmed the significance of Oxeon’s ultra light materials. InnovationsKapital invests in Nordic high-tech companies with strong growth. “Oxeon AB is a very exciting company with a unique product offering and with impressive customer traction. The company has a strong management team and we see this as a great opportunity to invest in a company with good growth and profitability”, says Staffan Ingeborn, responsible for InnovationsKapital’s investment in Oxeon. For more information, please contact: Staffan Ingeborn, Managing Director, InnovationsKapital, +46 31 60 91 90 staffan.ingeborn@innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 65 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 24 March, 2010 - InnovationsKapital: InnKap 4 Partners LP invests SEK 29.5 million in Gammadata AB to acquire shares and establish a long-term relationship

2010-06-10 09:47:43
Gammadata Group is established as a leader in the three areas of operations and serve customers across the globe. “We are very pleased to have InnKap 4 Partners as a new owner. We expect InnKap to support our promising plans, and to help us to take Gammadata forward”, says Jan Edhäll, CEO at Gammadata. InnovationsKapital invests in Nordic high-tech companies with strong growth. “Gammadata is a very interesting company with a unique product offering based on Nobel price winning technology. The company has a strong management team and we see this as a great opportunity to invest in a company with good growth, profitability and cash generation”, says Martin Falkevall, responsible for InnovationsKapital’s investment in Gammadata. For more information, please contact: Jan Edhäll CEO, Gammadata +46 18 480 58 00 www.gammadata.se Martin Falkevall Investment Director, InnovationsKapital +46 8 545 014 90 mf@innkap.se www.innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 65 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 23 April, 2010 - InnovationsKapital: The best investment of all time - InnovationsKapital and CapMan (Swedestart) for Altitun AB

2010-05-06 16:07:54

A new prize is instituted specifically for SVCAs 25th anniversary rewarding a private equity firm that has made an exceptionally successful investment. Motivation: An investment in a small seed company with negative cash flow came to be a jackpot for the entrepreneurs and investors when the company after a great journey got acquired by an industrial partner. The active ownership by private equity firms, combined with the portfolio company's unique high-tech competence came to be a success story that became a symbol of good entrepreneurship, innovation and commercialization. At the acquisition the VCs received incredible 87 times the money. The deal turned out to be glorious also for the Swedish taxpayers having invested in the research in the company. The sale of the company meant tax revenue to the Swedish state of entire SEK 1 billion. For further information, please contact: Staffan Ingeborg, Investment Director, InnovationsKapital +46 70-583 14 34 staffan.ingeborn@innkap.se www.innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 65 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 5 February, 2010 - InnovationsKaptial: Wind River to Add Virtutech Simics Products to Comprehensive Embedded Software Portfolio

2010-02-26 10:23:16

Wind River will sell and support Virtutech’s flagship development platform, Simics, as a stand-alone product and will continue to support all current architectures including ARM, Intel, MIPS and PowerPC. Simics will allow Wind River to offer a market-leading virtual systems development solution in a growing market segment of virtualization and simulation tools for device software development. “The addition of Virtutech’s development platforms to our product line will allow Wind River to offer greater value to customers across the entire product lifecycle and deepen current relationships with our broad set of silicon partners,” said Ken Klein, president, Wind River. “Time-to-market remains the single most challenging issue that sophisticated electronic equipment manufacturers need to address and ultimately control in order to remain competitive. With the addition of the Simics products, Wind River adds a key solution to further help customers improve time-to-market, as system complexity and ever more stringent demands upon overall system quality rapidly increase.” “Through our long-standing partnership with Wind River, it became evident that both companies shared a vision of how we can help the electronic systems market rethink how it goes about complex product development by deploying virtual platforms,” said John Lambert, CEO, Virtutech. “Time and again, Virtutech has helped customers and partners improve time-to-market by enabling the full sweep of systems development activities to take place on a virtual platform, freeing them up to apply new and innovative ways of running systems development projects. By combining with Wind River, we now have the opportunity to dramatically accelerate the spread of this key market trend and to bring the benefits of virtual platforms to a broader audience.” Simics provides binary-compatible hardware simulations that operate completely within a virtualized environment running on standard laptop or desktop PCs. This strategy allows OEMs to undertake critical software development activities on a virtual platform, independently of any hardware development schedules, semiconductor availability constraints or other limitations. This also allows semiconductor manufacturers to redefine complex system-on-chip development with greater ecosystem support and customer engagement. Virtutech therefore enables customers to manage complexity, drive improved quality and achieve higher productivity, all while lowering capital expenditure and shortening total development time. Acquired by Intel last year, Wind River develops operating systems, middleware (software found between an OS and software application), and software design tools for a variety of embedded computing systems. Its main products include VxWorks, the market-leading proprietary and multicore-ready real-time operating system, and commercial-grade Linux software platforms. The company also provides design services and software expertise, including custom-built solutions, development tools and device testing products. With thousands of customers, Wind River technology is relied upon by most major computer and networking communications companies, and is used by corporations and government agencies such as Alcatel-Lucent, BMW, Boeing, Bombardier Transportation, Mitsubishi, Motorola, NASA, Sony, Verizon and many more. Intel’s acquisition of privately-held Virtutech is expected to be completed this quarter. Terms of the deal are not being disclosed. About Virtutech Virtutech, Inc. is the leader in product development process improvement through virtualized systems development (VSD). Virtutech Simics® allows for a revolutionary change in the product development process at a full system level rather than a component level and is a commercial solution that uniquely delivers the four most important criteria for successful deployment of hardware virtualization in the electronics equipment development process: speed, scalability, model availability, and control. Simics customers report reduced time to market, better project risk management, lower capital expenditure, product development cost and maintenance as well as increased quality and individual productivity. Virtutech serves the needs of the world’s leading OEMs in the high-performance computing, aerospace and defense, telecommunications, networking and semiconductor industries. Customers include Cisco, Ericsson, Freescale Semiconductor, GE Avionics, Honeywell, IBM, Lockheed Martin, Nortel and Northrop Grumman. Virtutech is an active participant in organizations to drive adoption of VSD such as ARM Connected Community, Eclipse.org, IBM PartnerWorld, Multicore Association, Power.org, OSCI and Spirit Consortium. For more information, visit www.virtutech.com About Wind River Wind River, a wholly owned subsidiary of Intel Corporation (NASDAQ: INTC), is a world leader in embedded and mobile software. Wind River has been pioneering computing inside embedded devices since 1981 and its technology is found in more than 500 million products. Wind River is headquartered in Alameda, Calif. with offices in more than 15 countries. To learn more, visit Wind River at www.windriver.com or blogs.windriver.com CONTACTS Bryan Thomas Wind River Tel: +1 510-749-2414 bryan.thomas@windriver.com

innkapNews - 18 December, 2009 - InnovationsKapital: Microdata raises 10 million SEK to fund international expansion

2010-01-18 16:39:07

Microdata Telecom Innovation AB is raising 10 million SEK from venture capital firm InnovationsKapital and from existing shareholders through an equity issuance. Microdata Telecom is currently expanding internationally to address a rapidly growing global market for Microdata Advanced Site Solutions ( MASS™ ) in the mobile infrastructure market. Through this equity infusion, we are able to further expand our marketing and sales internationally with our portfolio of state of the art radio products within Advanced Site Solutions says Mats Gustavsson, CEO and co-founder of Microdata. We believe that InnovationsKapital will be a valuable partner as we grow the company. Microdata is led by an impressive team with solid experience both from the industry and from building companies, says Martin Falkevall from InnovationsKapital. We have been impressed by their early customer traction and are looking forward to an exciting journey together with the company in the coming years For further information, please contact: Mats Gustavsson CEO Microdata Telecom Innovation AB +46 708 15 69 25 mats.gustavsson@microdata.se Martin Falkevall InnovationsKapital Nordic Advisor AB +46 8 54 50 14 90 martin.falkevall@innkap.se Linda Höljö InnovationsKapital Nordic Advisor AB +46 8 54 50 14 90 linda.holjo@innkap.se Microdata Telecom Innovation AB offers cost effective radio solutions to OEMs and Network Operators, in order to improve radio coverage, capacity and quality of mobile communications. The company has offices in Täby, Sweden and in India. For further information, please visit: www.microdata.se InnovationsKapital was founded in 1994 as an independent private equity/venture capital firm focused on investments in growth companies. Our investment strategy is to invest in technology companies in the Nordic countries. InnovationsKapital has invested in over 60 companies and Carmen Systems, Formex, Kreatel, Nordnav and Spotfire are some examples of successful exits. InnovationsKapital currently advises four venture funds aggregating over 3 billion SEK (or about 300 million Euro), raised from well renowned Swedish and international institutional investors. For further information about InnovationsKapital, please visit our webpage: www.innkap.se

innkapNews - 8 December, 2009 - InnovationsKapital: Medius is raising external capital to fund international expansion

2009-12-08 09:20:21

Medius, which prior to the equity issuance had been owned by management and personnel, has grown organically and profitably every year since its founding in 2002. The last three years (2006-2008), the company’s revenue has increased by 430% and is on target to reach 90 million SEK (or about 9 million Euro) in 2009. A strategic plan for 2010-2012 includes offering part of the company’s products in non-domestic markets, and in 2012, 40% of revenue is planned to come from markets outside of the company’s home country. Medius is a well established company in Sweden with over 300 customers, including, among others, Saab, Haldex, Stadium, Mekonomen, K-rauta, and The Body Shop. This equity injection gives the company the opportunity to continue its rapid expansion in the rest of the Nordic countries, the Netherlands, Germany, the UK, and in France. Through this equity infusion, we are able to carry out the expansion plans that we have for the upcoming three years. We see an enormous market opportunity for our workflow platform offering, MediusFlow, in markets that we are planning to expand into in the years 2010 through 2012. Given that we in only a matter of a few years have become market leading in Sweden within certain applications – for example support for the purchase to payment process, where support for handling of invoicing has been wildly successful – we are confident that this international expansion will be successful as well, says Per Nordling, CEO and co-founder of Medius. We have been in discussions with a number of venture capital firms, and realized early on that InnovationsKapital was the best partner for Medius at this time. Through their prior investments they have shown good judgment and they take a long term perspective, Per Nordling continues. Medius has all the attributes that we look for in new investments – a great team, a strong and competitive customer offering, and a fast growing market, say Peder Holm and Fredrik Cronqvist from InnovationsKapital. We are looking forward to helping Medius and the existing shareholders in this upcoming expansion. For further information, please contact: Per Nordling CEO Medius AB +46-13-12 16 30 per.nordling@medius.se Peder Holm InnovationsKapital Nordic Advisor AB +46-8-54 50 14 90 peder.holm@innkap.se Fredrik Cronqvist InnovationsKapital Nordic Advisor AB +46-8-54 50 14 90 fredrik.cronqvist@innkap.se Medius aspires to deliver the world‘s best business system support covering all aspects from the requirement setting phase to, and including, the administration phase. This span is dealt with in three business areas: Consulting, ERP, and Workflow. For the Nordic market, Medius works within all three business areas. In the markets outside of the Nordic countries, Medius primarily focuses on the offerings of the Medius workflow business area, i.e. Workflow™. Medius is currently represented in Sweden (headquarters), the Nordic countries, the Netherlands, Germany, the UK, France, United Arab Emirates, and in Poland. Through our global partners we reach organizations all over the world. For further information, please visit: www.medius.se InnovationsKapital was founded in 1994 as an independent private equity/venture capital firm focused on investments in growth companies. Our investment strategy is to invest in technology companies in the Nordic countries. InnovationsKapital has invested in over 60 companies and Carmen Systems, Formex, Kreatel, Nordnav and Spotfire are some examples of successful exits. InnovationsKapital currently advises four venture funds aggregating over 3 billion SEK (or about 300 million Euro), raised from well renowned Swedish and international institutional investors. For further information about InnovationsKapital, please visit our webpage: www.innkap.se

innkapNews - 4 December 2009 - InnovationsKapital: PBM Sweden AB and InnovationsKapital initiate a long-term relation where InnKap 4 Partners LP initially invests SEK 7.5 million.

2009-12-07 15:55:17

Customers are mainly county councils, insurance companies and private companies. ”InnovationsKapital is a serious, long term and stabile investor with a strong track record of helping companies grow and realise their potential”, says the senior consultant Nils Edelstam (M.D.), PBM. PBM is currently based in six cities - Stockholm, Göteborg, Malmö, Gävle, Hudiksvall and Söderhamn. PBM plans to start further business in Sweden and the other Nordic countries. InnovationsKapital invests in young Nordic companies within the Healthcare & Life Sciences and ICT sectors. ”PBM is a very qualified company that continuously delivers excellent and lasting results to its customers. We are convinced that they will grow rapidly in this expansive market”, says Gunnar Fernström being responsible for InnovationsKapital’s investment in PBM. In total InnKap 4 Partners LP will invest up to SEK 19 million in this round of finance. For more information, please contact Tina Nikolaidou, Market Director, PBM, +46 70-569 28 82, www.pbm.se Gunnar Fernström, Investment Director, InnovationsKapital +46 70-312 05 02 gunnar.fernstrom@innkap.se www.innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. To date, over 65 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 30 June 2009 - InnovationsKapital: Projectplace’s new owners reinforces European strategy

2009-07-06 15:02:14

On Friday June 26, 2009, Projectplace International AB, Europe’s leading online project collaboration tool, was acquired by three venture capital companies. The buyers all have prior relationships with the company and good insight and understanding of its business. The ownership change is a step in the company's continued development and strengthens its future opportunities. - “We are already well established as the market leader in Sweden and Norway and are growing rapidly in Germany and the Benelux region. The new ownership provides us the ability to continue strengthening our position in existing markets while expanding in new European markets”, says Pelle Hjortblad, CEO, Projectplace International. Projectplace International’s business has been growing 30% per year the last three years. The turnover amounted to SEK 129 million in 2008. With the new owners on board the company see a strong opportunity for continued rapid expansion through organic growth as well as strategic acquisitions. - “We have had an eye on Projectplace International for a while”, says Anders Grånäs, Via Venture Partners. “When we got the opportunity to complete this deal, it was a very easy decision for us. The process has been fast and all parties agree.” - “Projectplace International is an innovative, well-run company with high development potential”, says Anders Ösund, Investor Growth Capital. “As an existing owner, we have followed the company for many years. With a clear Europe focused strategy, the company has a great opportunity to increase its growth rate further in coming years.” Investor Growth Capital, Via Venture Partners and InnovationsKapital will each own 30% of the company. The remaining 10% will be offered to a number of key employees within the company - “We are very pleased that the company's management and key employees want to invest and thereby take an active part in the company's continued development. We strongly believe that Projectplace has great potential and are very happy that the management clearly feels the same way”, says Magnus Berglind, InnovationsKapital. Contact: Projectplace International, Pelle Hjortblad, CEO, tel. +46 701810110 Investor Growth Capital, Anders Ösund, tel. +46 73 5241824 Via Venture Partners, Anders Grånäs, tel. +46 734441001 InnovationsKapital, Magnus Berglind, tel. +19175820396 Public Relations Projectplace International: Anna Ålenius Mathson, PR Manager Tel: +47 708 93 02 46, email: anna.alenius.mathson@projectplace.com Since 1998, Projectplace International has developed and provided Europe's leading web tool for project collaboration. The company, with 100 employees, is based in Stockholm, Sweden, with local offices in Denmark, Germany, The Netherlands, and Norway. For more information, please visit www.projectplace.com

innkapNews - 18 April, 2009 - InnovationsKapital: Ignis ASA Acquires Syntune AB

2009-04-20 11:37:18

The acquisition will widen the Ignis product range to include active components, and together with the existing passive components portfolio provide a broader optical offering to network operators. Ignis will issue 8.05 million shares as compensation for 100 % of the shares in Syntune AB to the sellers, which include the leading institutional investors InnovationsKapital and Vision Capital, and founders. Syntune will have a cash position of approximately SEK 25 million prior to the acquisition, and interest bearing debt of approximately SEK 41.8 million. In addition Syntune has established a new loan facility of EUR 2.3 million, Syntune's cash position is considered sufficient to fund its activities until break even during 2010. The company completed the qualification of its first generation of products in 2007. Ramp-up of revenue began at the end of 2007, and amounted to gross SEK 18 million in products sold in 2008, with a significant growth speed into 2009. With Syntune as a 100 % owned subsidiary, Ignis will strengthen its technology platform in a crucial area, tunable laser technology, and in addition get some of the best expertise in the optical industry. Tunability is becoming one of the most critical elements of the optical industry, as wavelength agility offers cost reductions and increased flexibility for optical network operators. Ignis ASA signed a Letter of Intent to acquire Syntune AB earlier in April. After the approval by the Board of Directors in Ignis, the acquisition remains contingent on approval by the General Meeting in Ignis ASA. By acquiring Syntune, Ignis maintains its strategy in taking an active part in the ongoing global industry consolidation. A detailed stock exchange notification about the transaction will follow on Monday the 20th of April. On the same day the company management will present further details about the acquisition at 10 am, at the Felix Conference Centre, Aker Brygge. The presentation will be published via webcast. See Ignis homepage. About Ignis ASA Ignis ASA comprises the business division Ignis Technology, which includes 69.3% ownership in Fi-ra Photonics in Korea and the wholly owned subsidiary Ignis Photonyx - with operations in Denmark, Norway and Canada. Fi-ra is first and foremost provider of optical splitters to large system houses and telecom operators in South-East Asia,while Ignis Photonyx over the last years has been focusing on investing in the development of AWG`s for the next generation high-capacity broadband network WDM-PON. About Syntune AB Syntune AB (www.syntune.com) supplies state-of-the-art widely tunable lasers for applications ranging from fiber-optic communications to sensor systems. In communications, Syntune's lasers enable universal DWDM transceivers with low power consumption in a small form factor. These drastically reduced overhead costs for sparing and maintaining inventories. Tunability also enables flexible networks, which allows operators to offer innovative services and reduces their operational expenditures. About InnovationsKapital InnovationsKapital is a leading independent venture capital firm in the Nordic region with capital commitments of EUR 317 million in four funds. Years of experience and a strong network within academia and industry enable us to invest in successful early stage and growth companies. We support talented entrepreneurs to help them create successful high growth businesses. Since 1994, we have made over 58 investments and a number of successful exits in the life sciences and technology sectors. For further information, please contact: Thomas Ramm, CEO, Ignis ASA Tel: +47 913 70 795

innkapNews - June 18, 2008 - InnovationsKapital: CapMan and InnovationsKapital invest in Crayon

2008-07-27 00:00:00

Crayon advises its clients in software procurement processes and simplifies the clients' software license administration. In addition Crayon offers consulting and training around the purchased software to its clients, which include a number of large Nordic customers within both private and public sectors. The company was founded in 2002 and it has headquarters in Oslo and offices in Trondheim, Stockholm, Umeå, Copenhagen and Helsinki. Crayon's net sales totalled some MEUR 48 in 2007 and the company employs some 190 people. “The company has a truly unique offering in software asset management, combining the work normally done by a value added reseller with skilled management consulting, which has resulted in a strong growth in sales and very satisfied customers”, says CapMan's Investment Director Julia Reuszner. “Crayon has a very strong market position both in Norway and Sweden and we believe there is potential to develop this further and address new geographies and a wider customer base”, says InnovationsKapital's Investment Director Martin Falkevall. “For us the investment made by CapMan and InnovationsKapital is a great acknowledgement of what Crayon has achieved over the last years .We believe that the investment can help us to the next level in our growth ambition”, says Crayon's Chairman of the Board Jens Rugseth. CapMan Technology 2007 fund and InnovationsKapital will own 20% of Crayon's parent company Artix's shares with equal holdings after the transaction has been completed. The current owners, including management and employees, will hold the reminder of the shares. The closing of the transaction is subject to certain conditions agreed with the parties in the transaction to be met. CapMan Plc is a substantial investor in CapMan Technology 2007 fund. For more information, please contact: Julia Reuszner, Investment Director, CapMan Technology tel. +46 8 545 854 70 or +46 739 865 664 Martin Falkevall, Investment Director, InnovationsKapital tel. +46 8 54 50 14 90 or +46 708 47 73 16 Jens Rugseth, Chairman of the Board, Crayon tel. +47 22 89 10 00 or +47 91 16 94 40 CapMan www.capman.com CapMan is one of the leading alternative asset managers in the Nordic countries and manages Nordic funds with approximately EUR 3.1 billion in total capital. CapMan has five investment areas (CapMan Buyout, CapMan Technology, CapMan Life Science, CapMan Russia and CapMan Real Estate), and each of them has a dedicated team and funds. Altogether CapMan employs 130 people in Helsinki, Stockholm, Copenhagen, Oslo and Moscow. CapMan was established in 1989 and its B shares are listed on the Helsinki Stock Exchange since 2001. InnovationsKapital www.innkap.se InnovationsKapital is a leading independent venture capital firm in the Nordic region with capital commitments of EUR 317 million in four funds. Years of experience and a strong network within academia and industry enable us to invest in successful early stage and growth companies. We support talented entrepreneurs to help them create successful high growth businesses. Since 1994, we have made over 58 investments and a number of successful exits in the life sciences and technology sectors. Crayon www.crayon.no Crayon is a successful provider of software asset management and licenses, consulting services and training courses. Established in 2002, Crayon has operations in Norway, Sweden, Finland and Denmark and employs 190 people.

innkapNews - July 8, 2008 - Xtract: Xtract, Innovator in Social Advertising Intelligence Raises EUR 7.5 Million

2008-07-08 00:00:00

London, UK and Helsinki, Finland – July 8, 2008: Xtract, the leader and innovator in social advertising intelligence today announced that it has closed its series B round of funding with EUR 7,5 Million ($11.74M) from leading early-stage technology investors Creandum, ETF III advised by Eqvitec Partners and InnovationsKapital. Xtract enables mobile and online companies to refine their customer data creating highly accurate 3 Dimensional profiles combining social interactions, behaviour and demographic information. It answers a crucial need in the advertising industry by making the advertising in social media and mobile effective. By using Xtract, customers have seen the average ad income increase with as much as 82% and in mobile campaigns response rates have increased, on an average, with 30%. Staffan Ingeborn, Managing Investment Director of InnovationsKapital comments: “Xtract is a very exciting company with a unique proposition for targeting of digital advertising. Its solutions have been shown to create substantial value for its customers, and we believe that Xtract is very well positioned to become a winner and a leader in this space.” Xtract works with over 50 companies with intensive customer data ranging from global leaders such as Nokia, T-Mobile and Vodafone to innovative challengers such as BLYK and Flirtomatic. Xtract makes complexity simple and actionable via a unique and patented set of products that based upon social interactions, behaviour data and other dataflow can create accurate and dynamic real-time customer profiles. Xtract can ensure delivery of the right audience to the right commercial message at the right time and accurately report on the effectiveness of any campaign. Something which up until now was not possible. Xtract board member Juha Mikkola of Eqvitec Partners said: “This investment opportunity had a lot of demand and clearly marks the very interesting market and expansion opportunity that Xtract represents in the fast growing social intelligence market.” “We are delighted to have added two new prominent investors, InnovationsKapital and Creandum in addition to our original investor ETF III advised by Eqvitec Partners. This investment round combined with an exceptional organic growth enables us to expand to new markets outside Europe,” says Kimmo Kiviluoto, CEO of Xtract. About Creandum Creandum is a Nordic venture capital firm investing in early-stage technology companies. The firm has 120 million Euros under management and is today the fastest growing independent partnership of its kind in the Nordic region. Creandum invests in innovative companies in high growth markets led by outstanding entrepreneurs. All investment professionals at Creandum have started companies or been part of successful startups. For more information, please visit www.creandum.com About Eqvitec Partners Oy Eqvitec Partners Oy is one of the largest technology focused venture capital and private equity firms in Northern Europe. The company was founded in 1997 and employs 15 investments professionals in Helsinki and Stockholm. Eqvitec Partners currently advises 6 funds with the total capital base of 500 million Euros. The funds invest in technology companies in all phases from start-up to buyouts. At the moment the funds have investments in 40 companies and have carried out 35 exits. More information can be found at www.eqvitec.com About InnovationsKapital InnovationsKapital is a leading independent venture capital firm in the Nordic region with capital commitments of EUR 317 million in four funds. Years of experience and a strong network within academia and industry enable InnovationsKapital to invest in successful early stage and growth companies. InnovationsKapital supports talented entrepreneurs to help them create successful high growth businesses. Since 1994, InnovationsKapital has made over 60 investments and a number of successful exits in the life sciences and technology sectors. For more information, please visit www.innkap.se About Xtract Xtract is the global trusted partner and innovator in Social Advertising Intelligence. We have the technology and competence to turn large user data into cash flow. Our solutions create accurate and automated consumer profiles for mobile and online advertisers based on social interactions, behavioural and demographic data. Xtract operates across Europe and Asia, working with over 50 companies with intensive customer data ranging from global leaders such as Nokia, T-Mobile and Vodafone to innovative challengers such as BLYK and Fonecta. Headquarters are in Helsinki, Finland and London, UK. www.xtract.com

innkapNews - June 27, 2008 - InnovationsKapital: Isconova secures 30 million Swedish kronor growth financing

2008-06-27 00:00:00

Leading vaccine adjuvant provider set to grow in animal vaccine market and to unlock the value of its technology for human vaccines. Uppsala, 27 June 2008. Isconova AB, announced today that it has secured financing of 30 million Swedish kronor ( 3,3 m€ ) from InnovationsKapital, a leading Nordic venture capital firm, and a group of private investors. Isconova is a pioneer in vaccine adjuvant technology, with a proprietary, safe and effective ISCOM technology. ”We are extremely pleased to have attracted the support of InnovationsKapital, who have a successful record of backing innovative growth biotech companies in Scandinavia. This new investment will allow Isconova to increase our production capacity and to invest in marketing,” said Bengt Falk, Isconova's CEO. “It will enable us to build on our existing growth in the animal vaccine sector. We will also be able to accelerate our activities in human vaccines where we already have a very promising partnership on an influenza vaccine.” Isconova's scientific excellence in the vaccine adjuvant field is backed by commercial validation through several agreements with major healthcare partners and on-market veterinary vaccines. “We feel excited about Isconova's future,” commented Johan Rask and Ulf Tossman at InnovationsKapital. Isconova's adjuvant makes vaccines more protective and longer-lasting. This fills a critical need for safe and effective adjuvants in the fast-growing vaccine industry. Isconova has established a significant production capacity in Uppsala and is already supplying its Matrix adjuvant to corporate partners for use in animal vaccines. For further information please contact: At Isconova: Bengt Falk, CEO, Isconova phone +46 703 022254 email bengt.falk@isconova.se At InnovationsKapital: Ulf Tossman, Investment Director, InnovationsKapital phone +46 705 630858 email ulf.tossman@innkap.se Johan Rask, Investment Manager, InnovationsKapital phone +46 708 946060 email johan.rask@innkap.se About Isconova AB, www.isconova.se Isconova, based in Uppsala, Sweden was established in 2000 by scientists from the Swedish Agricultural University. The Company's mission is to use its safe and effective ISCOM technology platform to deliver innovative vaccines. ISCOM is already established as the dominant vaccine adjuvant for horse vaccines in Europe. Isconova has licensed its technology to major vaccine corporations, including Intervet, Schering Plough, Pfizer and Crucell. Isconova will continue to drive growth by extending the use of its adjuvant into dogs, cats and livestock. New developments will allow Isconova to develop research projects to explore the use of ISCOM in human vaccines. About InnovationsKapital, www.innkap.se InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. To date, more than 60 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 317 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors.

innkapNews - June 11, 2008 - Syntensia: Syntensia Secures Expansion Financing - Leading Network Security-on-Demand Company Charts Further Growth in Emerging Markets

2008-06-11 00:00:00

NEW YORK, June 3, 2008 - Syntensia AB, a pioneer in subscription Network Security-On-Demand solutions, has secured financing of $3.5 million with an option for an additional $4 million through a share issue directed to InnovationsKapital, a leading Nordic venture capital firm, and a group of private investors in Sweden and abroad. Syntensia chairman is John Wattin. Syntensia, headquartered in Stockholm and with sales offices in twenty major Indian cities, Philippines and Cambodia was established in 2005 by Kaushik Thakkar. It focuses on providing all-in-one network security solutions for SMB in high growth emerging markets. "This investment allows Syntensia to continue our solid growth in India and our expansion in Cambodia and the Philippines," said Syntensia CEO Johan Hansson. "It also makes possible expansion into other Asian markets. We are particularly pleased to have attracted the support of InnovationsKapital, which has a reputation for backing innovative growth companies in Scandinavia." “Syntensia is capitalizing on the powerful combination of a low cost, high demand product offering to fast growing markets. We are very pleased with our investment in Syntensia and feel very excited about the company's potential,” said InnovationsKapital's Investment Director Magnus Berglind. Syntensia's WK product series is the most cost-effective and comprehensive network security solution for SMB available in the market today. These hardware-based appliances are Plug and Play ready, all-in-one network security solutions that integrate seven crucial security check points - Firewall, VPN, Intrusion Protection, Anti Virus, Spam Elimination, Surf Protection and Spyware Guarding and are available for a nominal subscription fee. Syntensia’s subscription model typically bundles everything into its single subscription fee, including automatic updates, maintenance and 24X7 technical support, thus enabling organizations to eliminate upfront costs, providing a predictable cost structure, and ensuring quality of service and the freedom to re-evaluate the solution decision any time. For further information please contact: Johan Hansson, CEO, Syntensia Phone: +1 917 582 0753 Email: johan@syntensia.com Magnus Berglind, Investment Director, InnovationsKapital Phone: +1 917 582 0396 Email: magnus.berglind@innkap.com InnovationsKapital InnovationsKapital (www.innkap.com) was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors. Syntensia AB Syntensia AB (www.syntensia.com) is a European Company headquartered in Stockholm, Sweden. Established in 2005, Syntensia is a pioneer in Security on-demand solutions sold on subscription basis. Syntensia focuses on providing all-in-one network security solutions for SMB in high growth emerging markets.

innkapNews - Sept 24, 2007 - InnovationsKapital: Apptus expands with help of InnovationsKapital

2007-09-24 00:00:00

Apptus Technologies AB - a Swedish challenger in the global market for search technology in the e-directory and e-commerce sector - announced today that InnovationsKapital, the leading Nordic private equity/venture capital fund has become a new investor in the company. Since its founding in 2000, Apptus Technologies has positioned itself as the leader in the e-directory and e-commerce sector in the Nordic countries. As a result, Apptus' technology platform is currently used by top tier customers such as, Eniro, Hitta and CDON.COM. In collaboration with InnovationsKapital, Apptus will increase its efforts on international expansion, continue the strong focus on sales and broaden the Apptus product portfolio. "With InnovationsKapital in our corner, we can scale up operations and take aggressive measures to become a leading international player in search technology. We have recently won our first customers in England and Canada, and we see this as a springboard out into the world," says Apptus CEO Michael Atlevi. "Apptus is a very exciting company with a unique offering to its customers, as well as strong and proven products and an impressive Nordic customer base. We are looking forward work with the Apptus team to build on their already widely successful Nordic presence. We strongly believe Apptus has the potential to become a dominating player in the global marketplace," says Martin Falkevall, Investment Director at InnovationsKapital. "Apptus position in the Nordic market has improved dramatically during 2007. We continue building our world class team, expand our product line and increase sales by 70 percent this year. InnovationsKapital will take an active role on our board of directors, bringing a strong track record and extensive experience in international expansion. We are launching several major initiatives for which we are well-equipped, thanks to our stable foundation, both when it comes finances and expertise," says Gertrud Elisabet Bohlin, Chairperson of the Board, Apptus Technologies AB. For more information, please contact: Gertrud Elisabet Bohlin, Chairwoman of the Board, Apptus Technologies AB Phone: +46 705-669526 E-mail: geb@queenab.se Martin Falkevall, Investment Director, InnovationsKapital Phone: +46 708- 47 73 16 E-mail: martin.falkevall@innkap.se More about Apptus Apptus Technologies AB is leading in search and database technology in the Nordic countries. The company provides solutions and products that assure availability for customers with growing data volumes and stringent demands on search logic, relevant results and connections to customers' operations. Apptus primarily supplies solutions to customers in the e-directory and e-commerce sector. Among the Nordic customers are Bokus, CDON.COM, De Gule Sider, Eniro, Hitta.se, Lunarstorm, Sveriges Radio, Torget Sverige, etc. Apptus conducts research in search and database technology. Apptus stands for quality, results and growth. For more information, please visit http://www.apptus.com. More about InnovationsKapital InnovationsKapital was founded in 1994 and is a leading early stage venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT, Healthcare & Life Sciences and Clean Tech - dynamic sectors that are rapidly expanding and where Nordic research plays an important role. InnovationsKapital currently advises four venture funds aggregating EUR 320 million in committed capital. The capital is provided by international institutional investors. For further information, please visit http://www.innkap.se

innkapNews - June 13, 2007 - InnovationsKapital: InnKap finansierar gräddan

2007-06-13 00:00:00

Innovationskapital handplockas endast de bästa projekten den skandinaviska marknaden och inför framtiden hoppas Gunnar Fernström, som är partner Innovationskapital och ansvarig för Health Careinvesteringar, att kunna finansiera bolag som kan erbjuda ny medicinsk teknik för att kunna avlasta sjukvården. "Generellt sett finansieras i dag färre bolag men kvaliteten bland dem som når marknaden har blivit betydligt högre," säger Fernström. Sedan Gunnar Fernström startade på Innovationskapital 1998 har branschen förändrats i positiv riktning. "Det har hänt enormt mycket under de senaste tio åren. Förutom att vi i dag är mycket noggrannare med vilka objekt vi väljer att finansiera, så har också medvetenheten och intresset bland forskarna för att kommersialisera resultat av sin forskning ökat markant," konstaterar Gunnar Fernström. "1998 var det ganska få som visade intresse för att gå ut i bolag med sitt forskningsresultat. I dag tror jag att de allra flesta som arbetar med forskning i olika program känner till att det finns möjlighet att starta verksamhet och att deras forskning kan komma ut i bolag." Innovationskapital investerar i de mest intressanta bolagen, främst i Skandinavien, med ett perspektiv på 5-7 år men ibland längre. Bolaget erbjuder stor expertis och nätverkskontakter under hela investeringsoch utvecklingsprocessen. Endast de bästa bolagen handplockas. "Förutsättningen för en finansiering är att produkten möter ett riktigt bra medicinskt behov som inte någon annan tillgodoser. Det kan vara både inom medicinsk teknik, läkemedel eller diagnostik," säger Gunnar Fernström. Framtidens bolag "Framtiden tror jag handlar om att hitta terapier inom medicinsk teknik som kan avlasta sjukvården genom att förkorta vårdtider och förbilliga vård. Forskningsresultat som leder till att människor kan behålla god livskvalitet, trots hög ålder, är viktiga saker," framhåller Fernström och funderar över förutsättningarna för morgondagens bolag. Fernström menar att det skulle vara av nytta för företagarvärlden om det inom universitetens ram skapades mer utrymme för entreprenörsbiten. Det skulle i sin tur leda till att mognare bolag plockades upp av venture bolagen. "Mot slutet av 2000-talet var det många bolag som kom till marknaden utan att de var riktigt mogna. Med mer 'mjuka pengar' in i universitetssystemet för att klara av de initiala finansieringarna som att söka de första patenten, skriva en affärsplan samt göra en marknadsundersökning, kommer förutsättningarna för lyckosamma affärer att öka ännu mer.

innkapNews - May 4, 2007 - InnovationsKapital: Hexaformer expands following investment from InnovationsKapital

2007-05-04 00:00:00

Hexaformer, a Swedish challenger on the global market for distribution transformers, today announced that the leading Nordic private equity/venture capital investment firm, InnovationsKapital, invests 30MSEK in the company. The investment makes it possible to expand sales and production for Hexaformer’s patented distribution transformers. During several years, Hexaformer has worked intensively to develop a new generation transformer, one that is significantly better and cheaper to produce compared to a conventional transformer. Up until now, Hexaformer has primarily sold prototypes, and smaller series of the new transformer – a total of 700 units have been sold to, among others, Vattenfall, Eon, Fortum, and Jämtkraft. “The investment from InnovationsKapital makes it possible to ramp up production and sales, and make an aggressive bet on becoming a leading vendor of distribution transformers to customer all over Europe. A fully automated production line, with an initial capacity of 1,500 transformers per year, is being built in Västervik”, says Magnus Palmstierna, CEO of Hexaformer. ”Hexaformer is a very exciting company with a unique value proposition, a strong patent portfolio, and a great market position in the Nordic countries”, says Martin Falkevall, Investment Director at InnovationsKapital. In connection to the investment from InnovationsKapital, the board of directors will be expanded and strengthened. Sören Swärd will be among those added to the board. Sören has extensive experience from the sector, and formerly served as the CEO of Siemens Sweden AB. “In my previous role as CEO of Siemens Sweden, I followed Hexaformer’s development during an extended period of time. The fact that Hexaformer’s transformers were significantly better than the conventional kind was something that I understood very early. I am now even more convinced about the products superiority, and I am excited to take part in the company’s plans for the future. I hope that my long industrial experience and the network that I have built up over the years will contribute positively to the company’s development going forward”, says Sören Swärd. For more information, please contact: Magnus Palmstierna, CEO, Hexaformer, telephone +46 70 590 15 65, e-mail: magnus.palmstierna@hexaformer.com Mattias Klintemar, CFO, Hexaformer, telephone +46 709 32 64 67, e-mail: mattias.klintemar@hexaformer.com Martin Falkevall, Investment Director, InnovationsKapital, telephone +46 708 47 73 16, e-mail: martin.falkevall@innkap.se About Hexaformer: Hexaformer is a Swedish company developing, manufacturing, and selling the market’s most efficient transformers and reactors. The transformers are covered by a global patent, based on an innovation by Lennart Höglund. Patent applications have also been filed for the company’s reactor solutions. The company is ramping up a large scale, highly automated production in Västervik. The company delivered its first hexatransformer for commercial use in year 2000, and has since delivered about 700 hexatransformers to a variety of customers, including smaller electricity boards, to large demanding customers such as Vattenfall, Eon, Fortum, Scania and Atlas Copco. The company has, up until InnovationsKapital’s investment, been financed by its CEO, Magnus Palmstierna, Bliwa Livförsäkring, Saminvest, and some 20 private investors. For more information, please visit our home page: http://www.hexaformer.com About InnovationsKapital: InnovationsKapital was founded in 1994 and is a leading venture capital firm for innovative growth companies. The business is focused on Nordic investments within Information & Communication Technology (ICT), Healthcare & Life Sciences and Clean Tech – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. InnovationsKapital has invested in over 55 companies, and examples of successful exits are Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Formex, Kreatel, Nordnav and Spotfire. InnovationsKapital currently advises four venture funds aggregating EUR 320 million in committed capital. The capital is provided by international institutional investors. For further information about InnovationsKapital, please visit our home page: http://www.innkap.se

innkapNews - May 3, 2007 - InnovationsKapital: Spotfire acquired for 195 MUSD - InnovationsKapital makes a return on investment of 9X in cash

2007-05-03 00:00:00

The IT company Spotfire has been acquired by TIBCO, a US software company quoted on Nasdaq. As a result of the deal, InnovationsKapital’s first fund, InnKap 1, can now be closed. The performance of this fund has been outstanding with investors receiving a return in excess of 7x on their investment. As a result InnKap 1 has achieved a unique position amongst the very best early stage European venture capital funds of this vintage. Spotfire achieved a return, in cash, of 9X of the investment and for InnovationsKapital, Spotfire is another success story in a line of recent successful investments. During the past year, thriving businesses such as Kreatel, Carmen Systems and Nordnav, have been sold with exceptional returns. “Since we started in 1994, we have completed almost 60 investments and achieved 30 exits. The exit in Carmen Systems last year was awarded “The Exit of The Year”, by both the Swedish Private Equity & Venture Capital Association and Nordic Unqoute. This continues to confirm that our early stage investment strategy is a successful model when the longer term perspective is taken””, says Staffan Ingeborn, CEO of InnovationsKapital and responsible for the investment in Spotfire. Outstanding result in InnKap 1 As a result of the exit in Spotfire, InnovationsKapital’s first fund can now be closed with this outstanding result. Four out of the eighteen investments in the fund have each yielded more than a 9X return on investment. “Those institutions who invested in our fund have received 7X the invested capital in net yield. It places us in a unique position in Europe. It’s exceptional to have so many first-rate investments in the same fund”, says Staffan Ingeborn. From research project to world leading company in ten years Spotfire, which was one of InnovationsKapital’s earlier investments, had its origins in a research project at Chalmers University of Technology which was led by Christopher Ahlberg, the CEO and founder. Today, ten years later, Spotfire is a global leader in its niche segment of the software market, with 7 out of 10 of the largest companies in the world on the customer list. Building for long term success “Many entrepreneurs are interested in an investment partnership with InnovationsKapital but we only invest in companies where we believe that there are good growth prospects on the international market. This proved to be the case for Spotfire, which is now joining our other success stories”, says Staffan Ingeborn. “Besides the necessary capital, InnovationsKapital have contributed with a great deal of experience in building growth companies together with an exceptional network of contacts. They helped us to think and act ‘as a business’ in a long term and focused way. Now, Spotfire is progressing well and is ready to take the next leap forward together with the new shareholders. This means that the business will progress and be further strengthened”, says Christopher Ahlberg, CEO and founder of Spotfire. Searching for “new Spotfires” ”We are on the hunt for new Spotfires. We are currently spending a significant amount of time and effort seeking new early stage high growth companies for InnKap 4, our latest fund. We have already found several very interesting investment opportunities which we believe will have every chance of succeeding, like Spotfire, and we will continue to work on them together with those potential pots of gold which we already have in our portfolio”, says Staffan Ingeborn. Media Enquiries: Staffan Ingeborn, CEO InnovationsKapital +46 (0)70 583 14 34 Advisors to the Investor Consortium and Management: • Financial: Goldman Sachs • Legal: Foley Hoag LLP InnovationsKapital was founded in 1994 and is a leading early stage venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT, Healthcare & Life Sciences and Clean Tech – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. InnovationsKapital currently advises four venture funds aggregating EUR 320 million in committed capital. The capital is provided by international institutional investors. For further information, please visit http://www.innkap.se